

Philip Scheltens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2896216/publications.pdf>

Version: 2024-02-01

1,386
papers

125,039
citations

246

143
h-index

209

311
g-index

1593
all docs

1593
docs citations

1593
times ranked

67073
citing authors

#	ARTICLE	IF	CITATIONS
1	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. Journal of the American Medical Directors Association, 2023, 24, 638-644.e1.	2.5	10
2	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. Alzheimer's and Dementia, 2023, 19, 285-295.	0.8	12
3	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
4	Description of a European memory clinic cohort undergoing amyloid PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
5	Early life involvement in C9orf72 repeat expansion carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 93-100.	1.9	16
6	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
7	Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography. Neurobiology of Aging, 2022, 111, 82-94.	3.1	5
8	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203
9	Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. Journal of Alzheimer's Disease, 2022, 86, 931-939.	2.6	7
10	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8
11	Research Criteria for the Behavioral Variant of Alzheimer Disease. JAMA Neurology, 2022, 79, 48.	9.0	44
12	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
13	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.1	10
14	Validation and test-retest repeatability performance of parametric methods for [11C]UCB-J PET. EJNMMI Research, 2022, 12, 3.	2.5	3
15	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	7.6	12
16	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, , .	1.2	1
17	Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. British Journal of Clinical Pharmacology, 2022, 88, 2814-2829.	2.4	7
18	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41

#	ARTICLE	IF	CITATIONS
19	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 31.	6.2	25
20	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Communications, 2022, 4, eac026.	3.3	4
21	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100141.	0.9	2
22	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.9	0
23	CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12240.	3.7	3
24	Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 38.	6.2	14
25	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
26	Spatial-Temporal Patterns of β -Amyloid Accumulation. Neurology, 2022, 98, .	1.1	40
27	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
28	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
29	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
30	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology, 2022, 98, .	1.1	17
31	Oscillatory Activity of the Hippocampus in Prodromal Alzheimer's Disease: A Source-Space Magnetoencephalography Study. Journal of Alzheimer's Disease, 2022, , 1-17.	2.6	4
32	Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study. Health and Quality of Life Outcomes, 2022, 20, 47.	2.4	4
33	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
34	The protective gene dose effect of the <i>APOE</i> ϵ 2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.8	13
35	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
36	Effects of age, amyloid, sex, and <i>APOE</i> ϵ 4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	5
38	Determining the Minimal Important Change of Everyday Functioning in Dementia. <i>Neurology</i> , 2022, 99, .	1.1	2
39	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
40	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .	1.1	8
41	Changes in Brain-Health Related Modifiable Risk Factors in Older Adults After One Year of COVID-19-Restrictions. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	4
42	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	5
43	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1499-1511.	3.9	14
44	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.8	30
45	Kinetics and 28-day test-retest repeatability and reproducibility of [¹¹ C]UCB-J PET brain imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1338-1350.	4.3	14
46	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.	0.8	17
47	Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2021, 268, 1222-1246.	3.6	120
48	Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. <i>JAMA Network Open</i> , 2021, 4, e2031654.	5.9	29
49	Risk of dementia in <i>APOE</i> $\epsilon 4$ carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	2.4	16
50	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.	2.7	13
51	Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	6.2	6
52	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	6.2	18
53	Amyloid β , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	3.7	9
54	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.	2.4	16

#	ARTICLE	IF	CITATIONS
55	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	2.6	2
56	Routine magnetoencephalography in memory clinic patients: A machine learning approach. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12227.	2.4	9
57	Aducanumab: Appropriate Use Recommendations. <i>Journal of prevention of Alzheimer's disease</i> , The, 2021, 8, 1-2.	2.7	4
58	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2169-2182.	6.4	24
59	In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 35.	6.2	47
60	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.	6.2	12
61	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.	2.6	10
62	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	4.6	85
63	Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis. <i>Brain and Cognition</i> , 2021, 148, 105660.	1.8	14
64	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.8	13
65	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. <i>Neurocase</i> , 2021, 27, 181-189.	0.6	2
66	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021, 89, 987-1000.	5.3	20
67	The predictive value of normal EEGs in dementia due to Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1038-1048.	3.7	3
68	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.8	44
69	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	1.3	10
70	Alzheimer's disease. <i>Lancet</i> , The, 2021, 397, 1577-1590.	13.7	1,530
71	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.	1.9	17
72	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.1	37

#	ARTICLE	IF	CITATIONS
73	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	2.6	8
74	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 106.	6.2	37
75	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.8	23
76	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 9736.	3.3	49
77	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	11.6	64
78	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
79	SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. <i>Cell Reports</i> , 2021, 35, 109259.	6.4	47
80	The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , 2021, 18, 17.	2.1	18
81	Plasma amyloid- β oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	6.2	19
82	Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24-months follow-up. <i>Brain and Behavior</i> , 2021, 11, e2257.	2.2	11
83	[¹⁸F]Flortaucipir PET Across Various <i>MAPT</i> Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.1	16
84	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	6.9	58
85	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminy cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD "VIVIAD". <i>Alzheimer's Research and Therapy</i> , 2021, 13, 142.	6.2	14
86	Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. <i>Acta Neuropathologica Communications</i> , 2021, 9, 131.	5.2	16
87	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	3.5	9
88	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	2.6	10
89	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, e1276-e1287.	1.1	44
90	Responding to responsive behaviour in Alzheimer's disease " Author's reply. <i>Lancet, The</i> , 2021, 398, 842.	13.7	1

#	ARTICLE	IF	CITATIONS
91	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	3.3	14
92	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	4.8	6
93	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. Neurobiology of Aging, 2021, 108, 146-154.	3.1	6
94	Comparing CSF amyloid- β biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12182.	2.4	26
95	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12189.	3.7	15
96	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 31, 102725.	2.7	9
97	Dutch Brain Research Registry for study participant recruitment: Design and first results. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12132.	3.7	23
98	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 750-759.	3.6	20
99	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
100	Dementia risk communication. A user manual for Brain Health Services" part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	6.2	21
101	Protocols for cognitive enhancement. A user manual for Brain Health Services" part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	6.2	15
102	The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, 1-6.	1.3	1
103	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services" part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	6.2	26
104	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services" part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
105	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicine, 2021, 9, 1610.	3.2	7
106	The Alzheimer's disease drug development landscape. Alzheimer's Research and Therapy, 2021, 13, 186.	6.2	49
107	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. Frontiers in Aging Neuroscience, 2021, 13, 761932.	3.4	4
108	Gut Microbiota Composition Is Related to AD Pathology. Frontiers in Immunology, 2021, 12, 794519.	4.8	57

#	ARTICLE	IF	CITATIONS
109	Psychosocial effects of Corona virus measures on (preâ€)dementia patients during 2 nd lockdown. Alzheimer's and Dementia, 2021, 17, e053995.	0.8	0
110	Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter?. Alzheimer's and Dementia, 2021, 17, .	0.8	0
111	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. Alzheimer's and Dementia, 2021, 17, .	0.8	0
112	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. Alzheimer's and Dementia, 2021, 17, .	0.8	1
113	Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
114	Capturing functional change in early Alzheimerâ€™s disease: Comparing instruments and scoring techniques to detect subtle decline. Alzheimer's and Dementia, 2021, 17, .	0.8	0
115	Identifying and characterizing patterns of functional decline in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.8	0
116	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. Alzheimer's and Dementia, 2021, 17, .	0.8	0
117	Rationale and design of the NEwTON study: A prospective cohort study of patients at risk of chronic traumatic encephalopathy. Alzheimer's and Dementia, 2021, 17, .	0.8	0
118	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
119	Subjective cognitive decline and selfâ€reported sleep at a memory clinic: The SCIENCE project. Alzheimer's and Dementia, 2021, 17, .	0.8	0
120	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.8	0
121	The Effect of Alzheimerâ€™s Disease-Associated Genetic Variants on Longevity. Frontiers in Genetics, 2021, 12, 748781.	2.3	7
122	Plasma Pâ€tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. Alzheimer's and Dementia, 2021, 17, .	0.8	0
123	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
124	EEG slowing in predementia Alzheimer's disease is compatible with neuronal hyperactivity: A multiscale computational modeling study.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053535.	0.8	0
125	Neuropathological hallmarks of Alzheimer's disease in centenarians, in the context of aging.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053600.	0.8	0
126	Neuroproteomics of cognitively healthy centenarians in the context of aging and Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053681.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.8	0
128	Parametric methods for [¹⁸ F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.	4.3	22
129	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. Journal of Neurology, 2020, 267, 144-152.	3.6	21
130	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1609-1617.	3.6	7
131	Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. Molecular Psychiatry, 2020, 25, 3380-3398.	7.9	120
132	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke, 2020, 51, 170-178.	2.0	115
133	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 256-264.	2.3	6
134	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. Alzheimer's Research and Therapy, 2020, 12, 10.	6.2	10
135	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
136	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease. Clinical Neurophysiology, 2020, 131, 88-95.	1.5	33
137	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical, 2020, 25, 102113.	2.7	5
138	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	2.6	8
139	Comorbid amyloid- β pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.	0.8	6
140	Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland. Health and Quality of Life Outcomes, 2020, 18, 323.	2.4	5
141	End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1169-1180.	2.6	5
142	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. Translational Psychiatry, 2020, 10, 332.	4.8	33
143	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiology of Aging, 2020, 96, 1-11.	3.1	7
144	Amyloid- β PET and CSF in an autopsy-confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	3.7	17

#	ARTICLE	IF	CITATIONS
145	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	10.2	254
146	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 116.	6.2	18
147	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, faa102.	3.3	11
148	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.1	55
149	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, e1672-e1685.	1.1	19
150	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 2-7.	1.5	4
151	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12021.	2.4	15
152	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020, 11, 585686.	2.6	52
153	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 148.	6.2	17
154	Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1519-1546.	2.6	27
155	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	4.8	42
156	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	3.3	4
157	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12060.	2.4	7
158	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12077.	2.4	5
159	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12083.	2.4	9
160	Association of amyloid- β CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020, 95, e2648-e2657.	1.1	33
161	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7
162	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ϵ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.	1.1	48

#	ARTICLE	IF	CITATIONS
163	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.8	43
164	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12063.	2.4	9
165	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	7.6	76
166	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.8	1
167	Amyloid- β CSF/PET discordance vs tau load 5 years later: It takes two to tangle. <i>Alzheimer's and Dementia</i> , 2020, 16, e037246.	0.8	0
168	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimer's and Dementia</i> , 2020, 16, e037912.	0.8	0
169	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEvELOP baseline results. <i>Alzheimer's and Dementia</i> , 2020, 16, e039306.	0.8	0
170	Associations of nutritional parameters with clinical progression in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, e039848.	0.8	0
171	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e040152.	0.8	0
172	Neuronal network hyperactivity in computational models of AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e040407.	0.8	0
173	MEG detects abnormal hippocampal activity in amyloid-positive MCI. <i>Alzheimer's and Dementia</i> , 2020, 16, e040796.	0.8	2
174	Interneuron hyperexcitability as both causal factor and risk factor in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040877.	0.8	3
175	Impact of the disclosure of amyloid-PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). <i>Alzheimer's and Dementia</i> , 2020, 16, e040952.	0.8	0
176	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e041048.	0.8	2
177	Early-onset Alzheimer's disease is related to differential spatial patterns of tau pathology and cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042041.	0.8	0
178	Beyond aphasia: Natural history of the aphasia onset dementia syndromes. <i>Alzheimer's and Dementia</i> , 2020, 16, e042105.	0.8	0
179	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042116.	0.8	0
180	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: The NUDAD project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042429.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Pronounced regional spectral, connectivity and network changes reflect visual deficits in posterior cortical atrophy: An EEG study on PCA. <i>Alzheimer's and Dementia</i> , 2020, 16, e042561.	0.8	0
182	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042614.	0.8	0
183	Differential diagnosis of dementia combining web-based cognitive testing and MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e042626.	0.8	0
184	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e042628.	0.8	1
185	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e042653.	0.8	0
186	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. <i>Alzheimer's and Dementia</i> , 2020, 16, e042687.	0.8	0
187	BDNF polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042728.	0.8	0
188	Biomarker testing in MCI patients: Deciding who to tap. <i>Alzheimer's and Dementia</i> , 2020, 16, e042735.	0.8	0
189	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.	0.8	0
190	A loss of neuronal inhibition best explains EEG abnormalities in preclinical Alzheimer's disease: A multiscale computational modeling study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043262.	0.8	0
191	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711.	0.8	0
192	Dutch Brain Research Registry for online study participant recruitment: Design and first results. <i>Alzheimer's and Dementia</i> , 2020, 16, e044738.	0.8	0
193	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044761.	0.8	0
194	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044783.	0.8	1
195	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044787.	0.8	1
196	Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044830.	0.8	1
197	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045112.	0.8	0
198	Using cerebrospinal fluid amyloid-beta (1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimer's and Dementia</i> , 2020, 16, e045128.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Serum neurofilament light in memory clinic practice. <i>Alzheimer's and Dementia</i> , 2020, 16, e045155.	0.8	0
200	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.8	0
201	Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.	0.8	0
202	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e045230.	0.8	1
203	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045236.	0.8	2
204	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045470.	0.8	0
205	A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimer's and Dementia</i> , 2020, 16, e045693.	0.8	2
206	Plasma amyloid- β oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.	0.8	0
207	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045770.	0.8	0
208	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18 F]florotau, [11 C]UCB-J and magnetoencephalography study. <i>Alzheimer's and Dementia</i> , 2020, 16, e045806.	0.8	0
209	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045829.	0.8	1
210	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.	0.8	0
211	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.	0.8	0
212	Increased 18 F-florotau load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing. <i>Alzheimer's and Dementia</i> , 2020, 16, e045911.	0.8	0
213	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.	0.8	0
214	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	6.2	14
215	CDH6 and HACH protein levels in plasma associate with Alzheimer's disease in APOE ϵ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	3.3	17
216	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	2.6	13

#	ARTICLE	IF	CITATIONS
217	A decade of Alzheimer's Research & Therapy: reflections on the past, present, and future. Alzheimer's Research and Therapy, 2020, 12, 67.	6.2	2
218	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	6.4	28
219	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
220	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.1	97
221	Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: "Window of Benefit". Journal of Alzheimer's Disease, 2020, 76, 671-679.	2.6	20
222	Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. NeuroImage: Clinical, 2020, 27, 102303.	2.7	4
223	Reproducibility of EEG functional connectivity in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 68.	6.2	73
224	A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. Nutrients, 2020, 12, 703.	4.1	21
225	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging, 2020, 93, 144.e1-144.e15.	3.1	7
226	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
227	Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. Cognitive and Behavioral Neurology, 2020, 33, 1-15.	0.9	21
228	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	2.6	13
229	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1436-1438.	2.5	1
230	Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology, 2020, 95, e662-e670.	1.1	28
231	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.8	257
232	Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study. JAMA Network Open, 2020, 3, e200094.	5.9	26
233	Fingerprinting Alzheimer's Disease by ¹ H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. Journal of Proteome Research, 2020, 19, 1696-1705.	3.7	32
234	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107.	3.1	34

#	ARTICLE	IF	CITATIONS
235	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	2.5	7
236	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	6.4	29
237	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
238	The Cognitive Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12020.	3.7	18
239	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology, 2020, 62, 1257-1263.	2.2	8
240	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17.	2.5	17
241	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 94, 71-80.	3.1	14
242	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	10.2	96
243	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
244	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. Brain Communications, 2020, 2, fcaa177.	3.3	10
245	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
246	Amyloid-Î² misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	6.2	31
247	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.1	31
248	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. Alzheimer's and Dementia, 2020, 16, .	0.8	2
249	White matter integrity disruption in early amyloid accumulators. Alzheimer's and Dementia, 2020, 16, e043021.	0.8	0
250	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12120.	2.4	7
251	TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Journal of prevention of Alzheimer's disease, The, 2020, 7, 1-11.	2.7	2
252	An Operational Definition of "Abnormal Cognition" to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. Journal of Alzheimer's Disease, 2020, 77, 1693-1703.	2.6	2

#	ARTICLE	IF	CITATIONS
253	Title is missing!. , 2020, 15, e0226784.		0
254	Title is missing!. , 2020, 15, e0226784.		0
255	Title is missing!. , 2020, 15, e0226784.		0
256	Title is missing!. , 2020, 15, e0226784.		0
257	Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. <i>Neurobiology of Learning and Memory</i> , 2019, 160, 132-138.	1.9	49
258	Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 726-728.	1.9	22
259	Quantification of [¹⁸ F]florbetapir: A test-retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.	4.3	22
260	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.	2.4	8
261	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	3.1	42
262	Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 520-528.	2.4	23
263	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 62.	6.2	40
264	Cognitive and functional progression of dementia in two longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1623-1632.	2.7	6
265	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471.	2.4	25
266	Cognitive reserve and clinical progression in Alzheimer disease. <i>Neurology</i> , 2019, 93, e334-e346.	1.1	85
267	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	3.6	11
268	Associations between quantitative [18F]florbetapir tau PET and atrophy across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 60.	6.2	40
269	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.1	51
270	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.8	18

#	ARTICLE	IF	CITATIONS
271	Amyloid- β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 83.	6.2	23
272	Cerebrospinal Fluid Amyloid- β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 15-20.	2.6	2
273	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 492-500.	3.7	5
274	“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia”. <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.	0.8	23
275	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	6.2	28
276	The “rights” of precision drug development for Alzheimer's™ disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	6.2	148
277	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
278	Re-aligning scientific and lay narratives of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2019, 18, 918-919.	10.2	31
279	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	6.2	40
280	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
281	Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 207-216.	1.3	1
282	Amyloid- β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.	3.4	37
283	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.	4.1	25
284	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's™ disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87
285	Cerebrospinal fluid collection: An informative animation video for patients and caregivers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 435-438.	2.4	4
286	White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1827-1834.	2.6	28
287	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.8	290
288	Gray matter T1 ρ /T2 ρ ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.	3.6	33

#	ARTICLE	IF	CITATIONS
289	A β 234 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, 2240.	12.8	39
290	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.	6.2	14
291	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.8	62
292	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019, 92, e2699-e2705.	1.1	10
293	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.	1.6	22
294	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019, 11, 1057.	4.1	10
295	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 383-391.	2.4	53
296	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 45.	6.2	19
297	Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1019-1030.	2.6	15
298	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.8	134
299	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	6.2	30
300	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	2.6	4
301	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A β 42, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	3.1	12
302	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	2.7	27
303	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.8	90
304	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
305	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.	3.1	41
306	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.	4.5	23

#	ARTICLE	IF	CITATIONS
307	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019, 77, 58-65.	3.1	14
308	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	2.6	16
309	F3â€1â€01: THE DIAGNOSTIC FRAMEWORK FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P863.	0.8	0
310	ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P87.	0.8	0
311	Can post-mortem MRI be used as a proxy for in vivo? A case study. <i>Brain Communications</i> , 2019, 1, fcz030.	3.3	17
312	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019, 16, 43.	2.1	16
313	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1515.	0.8	0
314	F2â€01â€01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P515.	0.8	0
315	ICâ€Pâ€025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P32.	0.8	0
316	ICâ€02â€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1.	0.8	0
317	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P68.	0.8	0
318	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
319	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. <i>Alzheimer's and Dementia</i> , 2019, 15, P24.	0.8	0
320	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. <i>Alzheimer's and Dementia</i> , 2019, 15, P84.	0.8	0
321	PET and CSF amyloid- β^2 status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	6.2	21
322	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.8	232
323	Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100â€Plus Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 759-767.	2.6	19
324	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	2.4	14

#	ARTICLE	IF	CITATIONS
325	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. <i>Neurobiology of Aging</i> , 2019, 75, 109-116.	3.1	22
326	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.8	37
327	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	3.6	27
328	Predicting progression in the late onset frontal lobe syndrome. <i>International Psychogeriatrics</i> , 2019, 31, 743-748.	1.0	6
329	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸ F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019, 60, 541-547.	5.0	47
330	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 73, 230.e9-230.e17.	3.1	7
331	Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2019, 27, 244-253.	2.8	46
332	Auditory hallucinations in adults with hearing impairment: a large prevalence study. <i>Psychological Medicine</i> , 2019, 49, 132-139.	4.5	30
333	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	2.4	9
334	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019, 3, e13417.	1.4	38
335	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	3.2	37
336	White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018, 66, 40-48.	3.1	20
337	Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 358-362.	2.4	13
338	An exploratory clinical study of p38 α kinase inhibition in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 464-473.	3.7	43
339	EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018, 67, 75-83.	3.1	21
340	Plasma Amyloid- β (A β 242) Correlates with Cerebrospinal Fluid A β 242 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1857-1863.	2.6	100
341	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839.	2.6	33
342	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861

#	ARTICLE	IF	CITATIONS
343	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	3.6	40
344	Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 569-579.	1.2	31
345	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.	1.1	28
346	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.	30.5	358
347	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.5	41
348	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 153-160.	2.4	12
349	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	2.4	7
350	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 707-722.	0.8	143
351	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.	6.2	20
352	Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1129-1139.	2.6	9
353	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.	0.8	20
354	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
355	Upward drift in cerebrospinal fluid amyloid β 2 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , 2018, 14, 62-70.	0.8	50
356	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	3.1	23
357	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	3.1	52
358	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	3.1	44
359	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
360	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β 1-42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	3.2	126

#	ARTICLE	IF	CITATIONS
361	Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 49-55.	2.4	77
362	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, e149-e156.	1.1	103
363	Assessing Fitness to Drive in Patients With Different Types of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 70-75.	1.3	26
364	P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1257.	0.8	0
365	O3-13-01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1054.	0.8	0
366	P1-476: CORTICAL T1W/T2W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P506.	0.8	0
367	O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPOM MAPPING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P259.	0.8	0
368	P2-470: DIFFERENT CO-LOCALIZATION OF NEUROINFLAMMATORY MARKERS IN PLAQUES OF ATYPICAL COMPARED TO TYPICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P903.	0.8	0
369	P3-216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1153.	0.8	0
370	IC-PA-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P180.	0.8	0
371	P2-270: INCREASED CSF AMYLOID β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P780.	0.8	0
372	P1-333: DETECTING CLINICALLY RELEVANT CHANGES IN DEMENTIA USING INSTRUMENTAL ACTIVITIES OF DAILY LIVING: A LONGITUDINAL VALIDATION STUDY WITH 3, 6, 9 AND 12 MONTHS FOLLOW-UP. <i>Alzheimer's and Dementia</i> , 2018, 14, P420.	0.8	0
373	IC-PA-066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P59.	0.8	0
374	IC-PA-182: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β -AMYLOID DEPOSITION IN THE BRAIN. <i>Alzheimer's and Dementia</i> , 2018, 14, P152.	0.8	1
375	P4-113: COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1482.	0.8	0
376	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1161.	0.8	0
377	P1-357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNG-ONSET DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P431.	0.8	0
378	P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-SCI STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P270.	0.8	0

#	ARTICLE	IF	CITATIONS
379	P1â€259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P380.	0.8	0
380	O2â€06â€03: AMYLOIDâ€P2 LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P632.	0.8	0
381	P2â€248: CONTACTINâ€2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P768.	0.8	0
382	ICâ€06â€05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P13.	0.8	0
383	O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	0.8	0
384	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P465.	0.8	0
385	ICâ€Pâ€092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P76.	0.8	1
386	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.8	0
387	P4â€106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.8	1
388	P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P401.	0.8	0
389	P2â€153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P726.	0.8	0
390	P3â€438: PARAMETRIC IMAGING OF [¹⁸ F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
391	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.8	0
392	P1â€627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€AD COHORT. Alzheimer's and Dementia, 2018, 14, P581.	0.8	0
393	P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P830.	0.8	0
394	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.8	0
395	P2â€134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€CONTROL STUDIES. Alzheimer's and Dementia, 2018, 14, P719.	0.8	0
396	P2â€360: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0

#	ARTICLE	IF	CITATIONS
397	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.8	0
398	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.8	0
399	P4â€038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. Alzheimer's and Dementia, 2018, 14, P1447.	0.8	0
400	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.8	0
401	O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. Alzheimer's and Dementia, 2018, 14, P657.	0.8	0
402	ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P79.	0.8	0
403	ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P37.	0.8	0
404	P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P1214.	0.8	0
405	ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P36.	0.8	0
406	P3â€272: A COMPARISON OF EEG CONNECTIVITY OUTCOME MEASURES FOR ALZHEIMER'S DISEASE IN A DOUBLEâ€BLINDED RANDOMIZED CLINICAL TRIAL OF PQ912. Alzheimer's and Dementia, 2018, 14, P1181.	0.8	0
407	ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P158.	0.8	2
408	P3â€277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS. Alzheimer's and Dementia, 2018, 14, P1183.	0.8	0
409	P3â€445: FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT. Alzheimer's and Dementia, 2018, 14, P1286.	0.8	0
410	P1â€291: BINDING PROPERTIES OF CURCUMIN IN POSTMORTEM BRAIN TISSUE: TOWARD AMYLOID IMAGING IN THE RETINA?. Alzheimer's and Dementia, 2018, 14, P397.	0.8	0
411	ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.8	0
412	F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.8	0
413	P1â€467: DISEASEâ€STAGEâ€SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.8	0
414	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P1058.	0.8	0

#	ARTICLE	IF	CITATIONS
415	O2â€09â€05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.	0.8	0
416	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
417	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.8	0
418	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	0.8	0
419	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. Alzheimer's and Dementia, 2018, 14, P789.	0.8	0
420	FTS3â€01â€02: EUROPEAN PERSPECTIVE ON CLINICAL AMYLOID IMAGING. Alzheimer's and Dementia, 2018, 14, P1004.	0.8	0
421	P2â€445: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P887.	0.8	1
422	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.8	1
423	WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-4.	2.7	7
424	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. Alzheimer's and Dementia, 2018, 14, P1366.	0.8	0
425	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	2.5	19
426	P3â€568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION. Alzheimer's and Dementia, 2018, 14, P1341.	0.8	0
427	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.	0.8	0
428	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.8	0
429	P2â€251: NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER'S DISEASE IN POSTMORTEM AD RETINAS. Alzheimer's and Dementia, 2018, 14, P770.	0.8	0
430	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	2.7	25
431	Heterogeneity of Alzheimerâ€™s disease: consequence for drug trials?. Alzheimer's Research and Therapy, 2018, 10, 122.	6.2	75
432	O1â€10â€05: ELECTROâ€ENCEPHALOGRAPHY AS A PRODROMAL MARKER OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P245.	0.8	0

#	ARTICLE	IF	CITATIONS
433	Computer-assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.4	8
434	P3-055: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.8	0
435	Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathologica Communications, 2018, 6, 147.	5.2	138
436	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain, 2018, 141, 3377-3388.	7.6	32
437	The plasma peptides of ovarian cancer. Clinical Proteomics, 2018, 15, 41.	2.1	33
438	The plasma peptidome. Clinical Proteomics, 2018, 15, 39.	2.1	22
439	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
440	Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
441	F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT LIGHT AND YKL40 TO A β , APOE ϵ 4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.8	0
442	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
443	Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
444	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
445	The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. European Journal of Epidemiology, 2018, 33, 1229-1249.	5.7	43
446	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
447	O3-09-06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1 ϵ 42 AND 1 ϵ 40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS. Alzheimer's and Dementia, 2018, 14, P1039.	0.8	4
448	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.8	0
449	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.8	0
450	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	7.6	102

#	ARTICLE	IF	CITATIONS
451	Safety, tolerability and efficacy of the glutamyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107.	6.2	80
452	ICA-1187: CORTICAL T1-TO-T2 RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. <i>Alzheimer's and Dementia</i> , 2018, 14, P156.	0.8	0
453	Clinical phenotype, atrophy, and small vessel disease in ϵ APOE ϵ 2 carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.	1.1	46
454	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.	5.3	230
455	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	6.2	48
456	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.	2.7	23
457	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	6.2	34
458	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 58.	6.2	21
459	EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 190.	3.4	48
460	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.	3.7	23
461	Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1091-1111.	2.6	228
462	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 455-462.	2.8	6
463	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 71-77.	2.6	2
464	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <i>Acta Neuropathologica Communications</i> , 2018, 6, 64.	5.2	36
465	An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. <i>Psychogeriatrics</i> , 2018, 18, 451-459.	1.2	10
466	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 111.	3.4	29
467	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	6.2	62
468	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2018, 71, 171-178.	3.1	25

#	ARTICLE	IF	CITATIONS
469	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	3.4	29
470	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.	6.2	94
471	Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 509-518.	2.4	19
472	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.	2.6	14
473	Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018, 15, 170.	7.2	30
474	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.	6.2	87
475	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	9.0	102
476	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.	1.0	3
477	Diagnostiek en classificatie van dementie. , 2018, , 15-29.		1
478	Patients to learn from: on the need for systematic integration of research and care in academic health care. <i>Journal of Clinical and Translational Research</i> , 2018, 3, 401-406.	0.3	1
479	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017, 22, 153-160.	7.9	102
480	Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.	1.3	12
481	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	2.6	60
482	Active A β 2 immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 10-22.	3.7	102
483	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
484	Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. <i>European Radiology</i> , 2017, 27, 3147-3155.	4.5	48
485	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.4	57
486	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.8	32

#	ARTICLE	IF	CITATIONS
487	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 130-138.	3.7	26
488	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A β 42 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 201-209.	2.4	19
489	Unbiased estimates of cerebrospinal fluid β -amyloid A β 42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 8.	6.2	60
490	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.8	423
491	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854.	3.6	69
492	Quantification of Tau Load Using [18F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	2.6	42
493	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.8	59
494	CSF ApoE predicts clinical progression in nondemented APOE ϵ 4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	3.1	26
495	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.	1.9	78
496	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE ϵ 4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 63-74.	2.6	32
497	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	3.6	59
498	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.	2.4	19
499	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017, 128, 1426-1437.	1.5	76
500	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017, 25, 973-981.	2.8	102
501	Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions. <i>Stroke</i> , 2017, 48, 1842-1848.	2.0	32
502	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
503	Glutamyl cyclase activity correlates with levels of A β peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 38.	6.2	24
504	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.	7.6	132

#	ARTICLE	IF	CITATIONS
505	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
506	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 99-106.	2.4	32
507	Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. <i>Ageing Research Reviews</i> , 2017, 36, 42-49.	10.9	10
508	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	3.1	60
509	Low normal cerebrospinal fluid A β 42 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	5.3	20
510	From corticocentrism to leucocentrism or both. <i>Brain</i> , 2017, 140, 247-250.	7.6	0
511	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975.	10.2	175
512	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.	2.6	34
513	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	9.0	77
514	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.	2.6	24
515	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	3.3	45
516	[ICP130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. <i>Alzheimer's and Dementia</i> , 2017, 13, P98.	0.8	0
517	[P1392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P417.	0.8	0
518	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.	2.4	56
519	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. <i>NeuroImage: Clinical</i> , 2017, 15, 673-681.	2.7	33
520	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	2.4	12
521	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	2.4	39
522	[P245]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN. <i>Alzheimer's and Dementia</i> , 2017, 13, P705.	0.8	0

#	ARTICLE	IF	CITATIONS
523	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523.	3.7	17
524	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	3.1	91
525	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	10.2	464
526	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 2.	6.2	98
527	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.	0.8	99
528	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.	4.5	97
529	A novel CCM2 variant in a family with nonprogressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 220-226.	1.7	6
530	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 50, 77-86.	3.1	6
531	Assessing fitness to drive: A validation study on patients with mild cognitive impairment. <i>Traffic Injury Prevention</i> , 2017, 18, 145-149.	1.4	27
532	[P1-244]: DISCRIMINATION BETWEEN DEMENTIA WITH LEWY BODIES (DLB), ALZHEIMER'S DISEASE (AD) AND MIXED PATHOLOGY USING ELECTROENCEPHALOGRAPHY (EEG). <i>Alzheimer's and Dementia</i> , 2017, 13, P338.	0.8	0
533	[P2-399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. <i>Alzheimer's and Dementia</i> , 2017, 13, P783.	0.8	0
534	[P2-473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P821.	0.8	0
535	[P3-161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A β 2 CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, P995.	0.8	0
536	[P3-226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1024.	0.8	0
537	[P3-375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1102.	0.8	0
538	[P3-386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. <i>Alzheimer's and Dementia</i> , 2017, 13, P1108.	0.8	1
539	[P3-407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1120.	0.8	0
540	[P3-422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1127.	0.8	0

#	ARTICLE	IF	CITATIONS
541	[P3â€“427]: NONâ€“AMNESTIC ALZHEIMER'S DISEASE: A POSSIBLE ROLE FOR NEUROINFLAMMATION?. Alzheimer's and Dementia, 2017, 13, P1131.	0.8	0
542	[P4â€“219]: [¹⁸ F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1352.	0.8	0
543	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
544	[P4â€“302]: DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT. Alzheimer's and Dementia, 2017, 13, P1406.	0.8	0
545	[ICâ€“Pâ€“005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“ β AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.8	1
546	[ICâ€“Pâ€“036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.8	0
547	[ICâ€“Pâ€“037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P33.	0.8	0
548	[ICâ€“Pâ€“053]: EARLY ALTERATIONS IN RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.8	0
549	[ICâ€“Pâ€“055]: EFFECT OF APOEâ€“ ϵ 2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.8	0
550	[ICâ€“Pâ€“058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
551	[ICâ€“Pâ€“065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0
552	[ICâ€“Pâ€“085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.	0.8	0
553	[ICâ€“Pâ€“095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P74.	0.8	0
554	[ICâ€“Pâ€“106]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.8	0
555	[ICâ€“Pâ€“110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.8	0
556	[ICâ€“Pâ€“203]: [¹⁸ F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.8	0
557	[ICâ€“Pâ€“206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.8	0
558	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€“OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.8	0

#	ARTICLE	IF	CITATIONS
559	[P1â€“276]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY. Alzheimer's and Dementia, 2017, 13, P355.	0.8	0
560	[P1â€“283]: RETINAL THICKNESS CORRELATES WITH PARIETAL CORTICAL ATROPHY ON MRI. Alzheimer's and Dementia, 2017, 13, P359.	0.8	0
561	[P1â€“289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€“PET) IN THE EMIFâ€“AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.8	0
562	[P1â€“387]: CHARACTERIZATION OF SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.	0.8	0
563	[P1â€“404]: EARLY ALTERATIONS IN RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.8	0
564	[P1â€“411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.8	0
565	[P1â€“440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.8	0
566	[P2â€“052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.	0.8	3
567	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“Î² AND [¹⁸ F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.8	0
568	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIFâ€“AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.8	1
569	[P2â€“335]: EFFECT OF APOE Î²2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.8	0
570	[F1â€“03â€“04]: BIOMARKERâ€“BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.8	0
571	[PLâ€“01â€“02â€“01]: BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P180.	0.8	0
572	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.8	0
573	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.8	0
574	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.8	0
575	[O2â€“05â€“01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.8	0
576	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.8	0

#	ARTICLE	IF	CITATIONS
577	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.8	0
578	[O2â€“12â€“03]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€“STATE MODEL ANALYSIS. Alzheimer's and Dementia, 2017, 13, P585.	0.8	4
579	[O3â€“06â€“04]: PROMINENT NONâ€“MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. Alzheimer's and Dementia, 2017, 13, P912.	0.8	0
580	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.8	3
581	[O5â€“07â€“04]: COGNITIVE PERFORMANCE AND ALZHEIMERâ€“ASSOCIATED PATHOLOGY IN THE CONTEXT OF EXTREME AGING. Alzheimer's and Dementia, 2017, 13, P1472.	0.8	0
582	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.8	0
583	[P2â€“194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.8	0
584	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.8	0
585	Psychosis in behavioral variant frontotemporal dementia. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1099-1106.	2.2	24
586	MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2017, 9, 107.	3.4	34
587	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience, 2017, 9, 117.	3.4	71
588	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 213.	3.4	12
589	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 2017, 60, 201-210.	2.6	11
590	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
591	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	6.2	25
592	A phase III randomized trial of gantenerumab in prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 95.	6.2	396
593	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	6.2	43
594	Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: â€“Growing into Deficits'. Dementia and Geriatric Cognitive Disorders Extra, 2017, 6, 500-507.	1.3	12

#	ARTICLE	IF	CITATIONS
595	Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 360-371.	0.7	10
596	Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 26-35.	2.4	58
597	CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER'S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. Journal of prevention of Alzheimer's disease, The, 2017, 4, 1-8.	2.7	34
598	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the 'Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment' (TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.	1.0	29
599	Cognitive Deficits in Patients With Neuropsychiatric Symptoms. Journal of Clinical Psychiatry, 2017, 78, e940-e946.	2.2	19
600	The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome. Journal of Clinical Psychiatry, 2017, 78, e1197-e1203.	2.2	18
601	Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	2.6	45
602	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.	2.6	14
603	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 49, 927-943.	2.6	41
604	Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. Frontiers in Neurology, 2016, 7, 161.	2.4	6
605	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience, 2016, 10, 238.	2.0	75
606	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
607	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.	7.3	58
608	White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. Dementia and Geriatric Cognitive Disorders, 2016, 41, 303-313.	1.5	3
609	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurology, 2016, 16, 242.	1.8	17
610	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
611	Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. Journal of Alzheimer's Disease, 2016, 53, 1287-1297.	2.6	58
612	Dementia and Rapid Mortality: Who is at Risk?. Journal of Alzheimer's Disease, 2016, 53, 135-142.	2.6	29

#	ARTICLE	IF	CITATIONS
613	Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1296-1302.	1.9	45
614	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. Journal of Alzheimer's Disease, 2016, 52, 875-885.	2.6	8
615	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2016, 51, 1249-1256.	2.6	12
616	P2ƒ: Applying Random Forest Machine Learning to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies: A Combination of Electroencephalography (EEG), Clinical Parameters and Biomarkers. Alzheimer's and Dementia, 2016, 12, P661.	0.8	5
617	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease. Journal of Alzheimer's Disease, 2016, 55, 521-537.	2.6	48
618	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
619	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 43-52.	2.4	42
620	P2Ý: Cerebral Blood Flow Measured with Phase–Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.8	0
621	P4z: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer’s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0
622	ICƖ: Quantification of TAU Load Using [¹⁸ F]AVᑑ and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.8	0
623	P1²: Impact of Co–Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.8	0
624	ICƖ: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.8	0
625	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
626	IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer’s Disease And Controls. , 2016, 12, P12-P12.		0
627	P1Ī: The Influence of Concomitant Alzheimer Pathology on Atrophy in Dementia with Lewy Bodies (DLB): A Comparative MRI Study. Alzheimer's and Dementia, 2016, 12, P535.	0.8	0
628	P1œ: Different Pathological Distribution Pattern of Phosphorylated TAU and Microglia in Amnesic and Non–Amnesic Alzheimer’s Disease. Alzheimer's and Dementia, 2016, 12, P558.	0.8	0
629	P2: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials. Alzheimer's and Dementia, 2016, 12, P614.	0.8	0
630	ICƖ: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.8	0

#	ARTICLE	IF	CITATIONS
631	ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.8	0
632	P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study. , 2016, 12, P678-P678.		0
633	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.8	0
634	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
635	P2â€282: EEGâ€Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, P738.	0.8	0
636	P2-300: Capturing Changes in Cognition: The Needs and Wishes of Dementia Researchers and Clinicians. , 2016, 12, P748-P748.		0
637	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.8	0
638	P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.8	0
639	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.		1
640	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.8	0
641	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.8	0
642	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.8	0
643	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.8	1
644	P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.8	0
645	P4â€215: Quantification of Tau Load Using [¹⁸ F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.8	0
646	P4â€224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.8	3
647	FTS3â€01â€03: Biomarkers for Vascular Contributions to Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.8	0
648	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0

#	ARTICLE	IF	CITATIONS
649	O1â€10â€01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P198.	0.8	3
650	FTS2-01-04: The Dutch Dementia Delta Plan (DDDP). , 2016, 12, P220-P220.		0
651	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.8	0
652	F5-05-01: THE PAST, PRESENT, AND FUTURE OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSESSMENTS IN ALZHEIMER'S DISEASE. , 2016, 12, P372-P373.		2
653	P1â€238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam Iadl Questionnaire. Alzheimer's and Dementia, 2016, 12, P498.	0.8	0
654	The Diagnostic and Prognostic Value ofâ€Neuropsychological Assessment inâ€Memory Clinic Patients. Journal of Alzheimer's Disease, 2016, 55, 679-689.	2.6	20
655	Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting. Journal of Alzheimer's Disease, 2016, 50, 797-806.	2.6	24
656	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
657	Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. Journal of Neuroinflammation, 2016, 13, 4.	7.2	54
658	Efficacy, Safety and Biomarker Data from SCarlet RoADâ€a Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD. American Journal of Geriatric Psychiatry, 2016, 24, S161-S162.	1.2	2
659	CSF and amyloid pet biomarker data from scarlet roadâ€ a global Phase 3 study of gantenerumab in patients with prodromal AD. Neurobiology of Aging, 2016, 39, S28-S29.	3.1	2
660	Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association, 2016, 17, 620-625.	2.5	7
661	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	3.7	4
662	Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 99-106.	2.4	50
663	Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	6.2	323
664	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders, 2016, 41, 210-219.	1.5	29
665	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. Lecture Notes in Computer Science, 2016, , 87-96.	1.3	19
666	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0

#	ARTICLE	IF	CITATIONS
667	O4â€09â€05: Risk Factors for Cognitive Decline are Age Dependent. Alzheimer's and Dementia, 2016, 12, P356.	0.8	0
668	ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.8	0
669	P2â€342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. Alzheimer's and Dementia, 2016, 12, P774.	0.8	0
670	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
671	Effect Size Analyses of Souvenaid in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1131-1139.	2.6	34
672	Bapineuzumab for mild to moderate Alzheimerâ€™s disease in two global, randomized, phase 3 trials. Alzheimer's Research and Therapy, 2016, 8, 18.	6.2	208
673	Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 242-251.	1.3	5
674	Validation of soluble amyloidâ€12 precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	3.9	17
675	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.	0.6	12
676	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.1	37
677	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 978-988.	3.6	48
678	Disrupted subjectâ€specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Human Brain Mapping, 2016, 37, 1194-1208.	3.6	25
679	Cortical phase changes measured using 7â€T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR in Biomedicine, 2016, 29, 1289-1294.	2.8	12
680	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders, 2016, 41, 16-26.	1.5	12
681	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Research Reviews, 2016, 25, 13-23.	10.9	455
682	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	7.3	79
683	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	4.5	99
684	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78

#	ARTICLE	IF	CITATIONS
685	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
686	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.	7.6	174
687	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 21-31.	3.1	40
688	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	10.2	1,242
689	Alzheimer's disease. <i>Lancet</i> , The, 2016, 388, 505-517.	13.7	2,430
690	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016, 41, 122-129.	3.1	52
691	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 872-881.	0.8	50
692	Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. <i>Stroke</i> , 2016, 47, 577-580.	2.0	7
693	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	3.1	51
694	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
695	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. <i>Brain Connectivity</i> , 2016, 6, 1-8.	1.7	18
696	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.	1.9	88
697	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	1.9	89
698	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 104-112.	1.3	2
699	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	7.6	58
700	IC-P-115: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data. , 2015, 11, P79-P79.		0
701	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
702	P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781.		0

#	ARTICLE	IF	CITATIONS
703	P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.		0
704	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
705	O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, P279-P279.		0
706	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 505-512.	2.4	81
707	IC-P-116: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. , 2015, 11, P79-P80.		0
708	IC-04-05: Multisite hippocampal subfields reproducibility: A european 3T study. , 2015, 11, P12-P12.		0
709	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.		0
710	P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P806-P806.		0
711	P1-093: Dementia and rapid mortality: Who's at risk?. , 2015, 11, P374-P374.		0
712	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
713	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 243-252.	2.6	35
714	Amyloid- β^2 Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	2.6	52
715	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
716	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 809-813.	2.6	42
717	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 635-647.	2.6	46
718	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 375-385.	1.3	21
719	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
720	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 889-899.	2.6	11

#	ARTICLE	IF	CITATIONS
721	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
722	O4-10-02: Cross-cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire. , 2015, 11, P293-P293.		0
723	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
724	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
725	IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P64-P64.		0
726	P3-182: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. , 2015, 11, P700-P701.		0
727	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
728	O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, P237-P238.		0
729	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 75-80.	2.4	4
730	P2-174: Multi-site hippocampal subfields reproducibility: A european 3T study. , 2015, 11, P558-P558.		0
731	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
732	Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 51.	6.2	38
733	Loss of <sc>EEG</sc><sc>N</sc>etwork <sc>E</sc>fficiency <sc>I</sc>s <sc>R</sc>elated to <sc>C</sc>ognitive <sc>I</sc>mpairment in <sc>D</sc>ementia <sc>W</sc>ith <sc>L</sc>ewy <sc>B</sc>odies. Movement Disorders, 2015, 30, 1785-1793.	3.9	65
734	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. Journal of Alzheimer's Disease, 2015, 49, 617-631.	2.6	330
735	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	1.4	22
736	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
737	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Frontiers in Human Neuroscience, 2015, 9, 474.	2.0	64
738	Trajectories of cognitive decline in different types of dementia. Psychological Medicine, 2015, 45, 1051-1059.	4.5	85

#	ARTICLE	IF	CITATIONS
739	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWC diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
740	The role of the orbitofrontal cortex in cognition and behavior. Reviews in the Neurosciences, 2015, 26, 1-11.	2.9	49
741	P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease. , 2015, 11, P873-P873.		0
742	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	3.6	196
743	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177.		0
744	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. NeuroImage: Clinical, 2015, 9, 418-429.	2.7	38
745	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
746	DT-01-02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease. , 2015, 11, P331-P331.		4
747	IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.		2
748	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0
749	IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias. , 2015, 11, P64-P65.		0
750	P4-087: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data. , 2015, 11, P805-P806.		0
751	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
752	F2-03-02: Early onset APOE-É4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.		1
753	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
754	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
755	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
756	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.		1

#	ARTICLE	IF	CITATIONS
757	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
758	FTS-04-01: Diagnostic impact of biomarkers including CSF and PET in a tertiary memory clinic. , 2015, 11, P263-P263.		0
759	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias. , 2015, 11, P288-P289.		0
760	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
761	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
762	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
763	DTâ€01â€03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet roadâ€a global, multicenter trial. Alzheimer's and Dementia, 2015, 11, P331.	0.8	14
764	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27
765	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. Neurolmage, 2015, 111, 562-579.	4.2	266
766	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 511-522.	0.8	55
767	White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews Neurology, 2015, 11, 157-165.	10.1	811
768	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.8	59
769	Prevalence and prognosis of Alzheimerâ€™s disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
770	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
771	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.8	254
772	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	3.1	49
773	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109
774	Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care. European Journal of Human Genetics, 2015, 23, 736-738.	2.8	7

#	ARTICLE	IF	CITATIONS
775	Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study. Dementia and Geriatric Cognitive Disorders, 2015, 40, 121-129.	1.5	4
776	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychological Medicine, 2015, 45, 1509-1519.	4.5	39
777	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
778	Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study. Journal of Alzheimer's Disease, 2015, 44, 471-480.	2.6	44
779	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	2.1	23
780	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. European Radiology, 2015, 25, 3050-3059.	4.5	80
781	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. Journal of the Neurological Sciences, 2015, 351, 18-23.	0.6	19
782	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. European Neuropsychopharmacology, 2015, 25, 1010-1017.	0.7	43
783	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	2.6	18
784	EFNS-EANS-EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. European Journal of Neurology, 2015, 22, 889-898.	3.3	110
785	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
786	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
787	Arterial stiffness and progression of structural brain changes. Neurology, 2015, 84, 448-455.	1.1	36
788	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.1	122
789	The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. Alzheimer Disease and Associated Disorders, 2015, 29, 45-49.	1.3	36
790	Microbleeds, Mortality, and Stroke in Alzheimer Disease. JAMA Neurology, 2015, 72, 539.	9.0	48
791	PLD3 variants in population studies. Nature, 2015, 520, E2-E3.	27.8	49
792	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	6.2	101

#	ARTICLE	IF	CITATIONS
793	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. BMC Neurology, 2015, 15, 145.	1.8	133
794	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. American Journal of Geriatric Psychiatry, 2015, 23, 1056-1066.	1.2	26
795	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke, 2015, 46, 2661-2664.	2.0	73
796	The sensitivity to change over time of the Amsterdam IADL Questionnaire. Alzheimer's and Dementia, 2015, 11, 1231-1240.	0.8	40
797	Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference. Journal of the American Medical Directors Association, 2015, 16, 731-739.	2.5	222
798	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology, 2015, 72, 1275.	9.0	183
799	7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. Neurobiology of Aging, 2015, 36, 20-26.	3.1	43
800	The Two-Year Incidence of Depression and Anxiety Disorders in Spousal Caregivers of Persons with Dementia: Who is at the Greatest Risk?. American Journal of Geriatric Psychiatry, 2015, 23, 293-303.	1.2	126
801	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. International Journal of Geriatric Psychiatry, 2015, 30, 744-750.	2.7	51
802	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	2.5	72
803	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. PLoS ONE, 2014, 9, e102995.	2.5	56
804	SUCLG2 identified as both a determinant of CSF A β 42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	2.9	45
805	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. Brain Connectivity, 2014, 4, 337-346.	1.7	69
806	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. Journal of Neurology, 2014, 261, 2085-2092.	3.6	10
807	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
808	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.1	51
809	Prevalence of cortical superficial siderosis in a memory clinic population. Neurology, 2014, 82, 698-704.	1.1	71
810	THE COMBINATION OF HIPPOCAMPAL ATROPHY ON MRI AND CSF IS A BIOMARKER FOR FRONTOTEMPORAL DEMENTIA IN EARLY ONSET DEMENTIA. , 2014, 10, P287-P288.		0

#	ARTICLE	IF	CITATIONS
811	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. Radiology, 2014, 270, 205-211.	7.3	72
812	Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on 'Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cutoffs'. Journal of Internal Medicine, 2014, 275, 331-333.	6.0	13
813	Amyloid and its association with default network integrity in Alzheimer's disease. Human Brain Mapping, 2014, 35, 779-791.	3.6	37
814	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2665-2670.	3.1	28
815	Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. Alzheimer's Research and Therapy, 2014, 6, 86.	6.2	44
816	Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease and Associated Disorders, 2014, 28, 206-218.	1.3	529
817	O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, P219-P219.		0
818	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	9.0	140
819	Using Magnetic Resonance Imaging in Diagnosing Dementia: A Dutch Outpatient Memory Clinics Survey. Dementia and Geriatric Cognitive Disorders, 2014, 38, 281-285.	1.5	2
820	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	1.2	30
821	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. European Radiology, 2014, 24, 397-404.	4.5	27
822	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1190-8.	6.4	7
823	An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 692-698.	1.9	98
824	Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia. Dementia and Geriatric Cognitive Disorders, 2014, 38, 55-64.	1.5	33
825	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
826	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
827	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology, 2014, 261, 1160-1169.	3.6	16
828	White Matter Hyperintensities and Cognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. American Journal of Geriatric Psychiatry, 2014, 22, 157-166.	1.2	25

#	ARTICLE	IF	CITATIONS
829	Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. <i>Diabetologia</i> , 2014, 57, 2208-2214.	6.3	40
830	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 27.	6.2	63
831	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014, 2, 79.	5.2	25
832	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.	3.6	108
833	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	10.2	302
834	Comparison of Simplified Parametric Methods for Visual Interpretation of ¹¹ C-Pittsburgh Compound-B PET Images. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1305-1307.	5.0	24
835	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014, 24, 2326-2333.	4.5	50
836	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014, 10, 456-467.	0.8	16
837	No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. <i>Neurobiology of Aging</i> , 2014, 35, 1956.e9-1956.e11.	3.1	26
838	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1596-1604.	3.1	46
839	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S299-305.	0.8	31
840	The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 1-9.	1.8	25
841	The cerebrospinal fluid 'Alzheimer profile': Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.8	249
842	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 85-90.	2.3	17
843	A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 715-717.	2.6	30
844	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	2.6	307
845	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 801-807.	2.6	109
846	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 47.	6.2	24

#	ARTICLE	IF	CITATIONS
847	Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 261-271.	2.6	75
848	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.		1
849	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
850	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.		0
851	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, P349-P349.		1
852	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
853	P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE. , 2014, 10, P638-P638.		1
854	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.		0
855	O4-06-02: CSF AD-PROFILE IN DEMENTIA WITH LEWY BODIES: EFFECT ON CLINICAL PARAMETERS AND COGNITIVE DECLINE. , 2014, 10, P261-P262.		0
856	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
857	O2-08-06: THE FUTURE OF CARE: THE DIGITAL ALZHEIMER CENTER-EVALUATION OF AN ONLINE PORTAL FOR PATIENTS WITH DEMENTIA AND THEIR INFORMAL CAREGIVERS. , 2014, 10, P181-P182.		0
858	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
859	O4-11-04: ACTIVE A β 2 IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS. , 2014, 10, P274-P274.		2
860	P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM. , 2014, 10, P309-P309.		0
861	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456.		0
862	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
863	P1-381: EFFECTS OF THE MEDICAL FOOD SOUVENOID ON PLASMA NUTRIENT LEVELS IN MILD ALZHEIMER'S DISEASE DURING 48 WEEKS. , 2014, 10, P454-P454.		0
864	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0

#	ARTICLE	IF	CITATIONS
865	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS. , 2014, 10, P32-P33.		0
866	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.		0
867	P3-403: CAPTURING CHANGES IN EVERYDAY FUNCTIONING. , 2014, 10, P778-P778.		0
868	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
869	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI. , 2014, 10, P265-P265.		1
870	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.		1
871	O1-09-06: A EUROPEAN BIOBANK FOR THE VALIDATION OF NEW MARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASE: THE BIOMARKAPD PROJECT. , 2014, 10, P148-P148.		0
872	O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA. , 2014, 10, P197-P198.		0
873	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.		0
874	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61.		1
875	P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, P349-P349.		0
876	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
877	P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS. , 2014, 10, P389-P390.		0
878	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA-TWO SIDES OF THE SAME COIN?. , 2014, 10, P543-P543.		1
879	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
880	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.		0
881	O2-08-05: THE DIGITAL ALZHEIMER CENTER: A NEXT STEP TOWARD INNOVATIVE DEMENTIA CARE. , 2014, 10, P181-P181.		0
882	O2-13-01: PREVALENCE AND PROGNOSIS OF PRODROMAL ALZHEIMER'S DISEASE: A COMPARISON OF THE INTERNATIONAL WORKING GROUP CRITERIA AND NATIONAL INSTITUTE OF AGING-ALZHEIMER'S ASSOCIATION CRITERIA. , 2014, 10, P193-P193.		0

#	ARTICLE	IF	CITATIONS
883	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
884	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, P663-P663.		1
885	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.		0
886	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
887	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.		0
888	P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS. , 2014, 10, P916-P917.		0
889	The Effect of Souvenaid on Functional Brain Network Organisation in Patients with Mild Alzheimer's Disease: A Randomised Controlled Study. PLoS ONE, 2014, 9, e86558.	2.5	95
890	Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. , 2014, , 185-211.		1
891	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathologica Communications, 2014, 2, 79.	5.2	18
892	Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study. Cerebrovascular Diseases, 2013, 35, 544-553.	1.7	65
893	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology, 2013, 260, 1014-1021.	3.6	34
894	Blood Pressure and Progression of Brain Atrophy. JAMA Neurology, 2013, 70, 1046.	9.0	42
895	Mild cognitive impairment and amyloid and beyond. Nature Reviews Neurology, 2013, 9, 493-495.	10.1	6
896	Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews. Dementia and Geriatric Cognitive Disorders, 2013, 36, 211-228.	1.5	47
897	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
898	Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1250-1254.	1.9	68
899	Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.	3.1	19
900	The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials, 2013, 14, 305.	1.6	26

#	ARTICLE	IF	CITATIONS
901	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. <i>Neurobiology of Aging</i> , 2013, 34, 73-82.	3.1	41
902	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013, 34, 128-136.	3.1	145
903	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013, 34, 2003-2013.	3.1	86
904	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
905	O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia. , 2013, 9, P526-P526.		0
906	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.		19
907	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2014-2022.	3.1	156
908	Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.	1.1	204
909	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
910	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.	3.1	66
911	Cerebrospinal fluid A β 42 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.	0.8	164
912	Preface. <i>Medical Clinics of North America</i> , 2013, 97, xiii-xv.	2.5	4
913	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013, 9, 276-283.	0.8	25
914	Diffusion changes predict cognitive and functional outcome: The LADIS study. <i>Annals of Neurology</i> , 2013, 73, 576-583.	5.3	66
915	An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion. <i>American Journal of Neuroradiology</i> , 2013, 34, 1550-1555.	2.4	40
916	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.	1.1	110
917	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.	3.1	355
918	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013, 9, 262-268.	0.8	22

#	ARTICLE	IF	CITATIONS
919	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. Alzheimer's Research and Therapy, 2013, 5, 26.	6.2	1
920	International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 363-368.	2.5	72
921	Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. NeuroImage, 2013, 66, 28-35.	4.2	85
922	Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's Research and Therapy, 2013, 5, 56.	6.2	51
923	Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain, 2013, 136, 2707-2716.	7.6	111
924	Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 269-278.	1.3	8
925	The Association Between APOE ϵ 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
926	Validation of the Amsterdam IADL Questionnaire [®] , a New Tool to Measure Instrumental Activities of Daily Living in Dementia. Neuroepidemiology, 2013, 41, 35-41.	2.3	65
927	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology, 2013, 267, 221-230.	7.3	206
928	Differential effect of APOE ϵ genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.1	99
929	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.1	161
930	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.1	122
931	Assessment of Instrumental Activities of Daily Living in Dementia. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 244-250.	2.3	45
932	Longitudinal Amyloid Imaging Using ¹¹ C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	5.0	148
933	Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	1.5	41
934	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920.	4.5	93
935	Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β -peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 179-187.	3.0	18
936	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 169-178.	2.6	21

#	ARTICLE	IF	CITATIONS
937	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	2.6	21
938	Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.	1.1	21
939	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 59.	6.2	80
940	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ϵ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 563-570.	2.6	19
941	Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.	2.5	107
942	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 58.	3.4	143
943	Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. <i>PLoS ONE</i> , 2013, 8, e53455.	2.5	44
944	Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old. <i>Current Alzheimer Research</i> , 2013, 10, 1090-1097.	1.4	12
945	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.1	129
946	Exercise and Early-Onset Alzheimer's Disease: Theoretical Considerations. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 132-145.	1.3	18
947	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.	7.6	109
948	Lessons Learned in Eastern Europe. , 2012, , 99-103.		0
949	Microbleeds in dementia—singing a different ARIA. <i>Nature Reviews Neurology</i> , 2012, 8, 68-70.	10.1	10
950	Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 101-108.	2.6	156
951	Blood—brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012, 135, 181-189.	7.6	252
952	Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates: Table 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1038-1040.	1.9	47
953	White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.	2.0	88
954	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. <i>Current Alzheimer Research</i> , 2012, 9, 902-912.	1.4	42

#	ARTICLE	IF	CITATIONS
955	MRI-based biomarkers of preclinical AD. <i>Neurology</i> , 2012, 78, 80-81.	1.1	4
956	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	2.6	73
957	Efficacy of Souvenaid in Mild Alzheimer's Disease: Results from a Randomized, Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 225-236.	2.6	256
958	Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 459-469.	2.6	35
959	Identifying target groups for the prevention of depression among caregivers of dementia patients. <i>International Psychogeriatrics</i> , 2012, 24, 298-306.	1.0	34
960	Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 314-322.	1.8	15
961	Physical Activity Prevents Progression for Cognitive Impairment and Vascular Dementia. <i>Stroke</i> , 2012, 43, 3331-3335.	2.0	98
962	<sc>EFNS</sc> Guidelines on the diagnosis and management of disorders associated with dementia. <i>European Journal of Neurology</i> , 2012, 19, 1159-1179.	3.3	239
963	Increased skin temperature in Alzheimer's disease is associated with sleepiness. <i>Journal of Neural Transmission</i> , 2012, 119, 1185-1194.	2.8	14
964	No Evidence for Additional Blood-Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1468-1471.	4.3	18
965	P-Glycoprotein Function at the Blood-Brain Barrier: Effects of Age and Gender. <i>Molecular Imaging and Biology</i> , 2012, 14, 771-776.	2.6	127
966	A new informant-based questionnaire for instrumental activities of daily living in dementia. <i>Alzheimer's and Dementia</i> , 2012, 8, 536-543.	0.8	80
967	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 560-563.	0.8	47
968	S201: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. <i>Alzheimer's and Dementia</i> , 2012, 8, P228.	0.8	0
969	Discrepancy Between Subjective and Objective Sleep Disturbances in Early- and Moderate-Stage Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 460-467.	1.2	80
970	O401: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, P618.	0.8	0
971	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 61-5.	2.3	21
972	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. <i>Neurobiology of Aging</i> , 2012, 33, 201.e1-201.e8.	3.1	48

#	ARTICLE	IF	CITATIONS
973	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.	3.1	125
974	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	3.1	346
975	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 627.e1-627.e12.	3.1	74
976	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	3.1	52
977	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.	3.1	337
978	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012, 33, 1008.e25-1008.e31.	3.1	34
979	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	3.1	55
980	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	3.1	75
981	68 Cerebral microbleeds: identification, prevalence and clinical relevance. <i>Neurobiology of Aging</i> , 2012, 33, S30.	3.1	0
982	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.	1.1	72
983	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148.	1.9	24
984	Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 340-349.	3.8	61
985	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, 85.	1.9	24
986	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. <i>BMC Neurology</i> , 2012, 12, 72.	1.8	24
987	Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012, 12, 75.	1.8	14
988	Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. <i>Brain Connectivity</i> , 2012, 2, 45-55.	1.7	85
989	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 3085-3093.	4.2	190
990	Leeftijd: een belangrijke factor voor cognitieve profielen van de ziekte van Alzheimer. <i>Neuropraxis</i> , 2012, 16, 183-191.	0.1	0

#	ARTICLE	IF	CITATIONS
991	Bloodâ€‘brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Research, 2012, 2, 57.	2.5	53
992	Does a Family Meetings Intervention Prevent Depression and Anxiety in Family Caregivers of Dementia Patients? A Randomized Trial. PLoS ONE, 2012, 7, e30936.	2.5	74
993	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	6.4	145
994	Reproducibility of quantitative (R)-[11C]verapamil studies. EJNMMI Research, 2012, 2, 1.	2.5	45
995	Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer's Disease. PLoS Computational Biology, 2012, 8, e1002582.	3.2	336
996	Effectiveness of Family Meetings for Family Caregivers on Delaying Time to Nursing Home Placement of Dementia Patients: A Randomized Trial. PLoS ONE, 2012, 7, e42145.	2.5	21
997	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 126-135.	1.9	588
998	Normal Ageing. , 2011, , 43-57.		5
999	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. Journal of the Neurological Sciences, 2011, 307, 100-105.	0.6	57
1000	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	5.7	119
1001	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	5.7	62
1002	Progression from MCI to AD: Predictive value of CSF A β 242 is modified by APOE genotype. Neurobiology of Aging, 2011, 32, 1372-1378.	3.1	12
1003	2001â€‘2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. Cerebrovascular Diseases, 2011, 32, 577-588.	1.7	258
1004	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€‘Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
1005	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
1006	How golden is the gold standard of neuropathology in dementia?. Alzheimer's and Dementia, 2011, 7, 486-489.	0.8	65
1007	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimerâ€™s Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
1008	Complexity of MRI White Matter Hyperintensity Assessments in Relation to Cognition in Aging and Dementia from the Sunnybrook Dementia Study. Journal of Alzheimer's Disease, 2011, 26, 379-388.	2.6	39

#	ARTICLE	IF	CITATIONS
1009	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.	2.6	21
1010	Self-Perceived Memory Complaints Predict Progression to Alzheimer Disease. The LADIS Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 491-498.	2.6	21
1011	The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. <i>European Journal of Neurology</i> , 2011, 18, 279-285.	3.3	42
1012	The World of Dementia Beyond 2020. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 923-927.	2.6	73
1013	Do Instrumental Activities of Daily Living Predict Dementia at 1â€•and 2â€•Year Followâ€•Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia<scp>A</scp>lzheimer's Disease Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2273-2281.	2.6	59
1014	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE É4 allele. <i>Lancet Neurology</i> , The, 2011, 10, 280-288.	10.2	273
1015	New lexicon and criteria for the diagnosis of Alzheimer's disease â€• Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301.	10.2	7
1016	Utility of imaging for nutritional intervention studies in Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2011, 668, S59-S69.	3.5	16
1017	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.	4.5	299
1018	Heterogeneity in age-related white matter changes. <i>Acta Neuropathologica</i> , 2011, 122, 171-185.	7.7	271
1019	Efficacy of a medical food on cognition in Alzheimer's Disease: Results from secondary analyses of a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 720-724.	3.3	45
1020	Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: Secondary analyses from a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 672-676.	3.3	30
1021	Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation: â€•Last inâ€•first outâ€•™. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 699-714.	6.1	51
1022	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.	2.0	124
1023	Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 373-377.	1.9	32
1024	Regional Differences in Effects of <i>APOE</i> É4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.	1.5	18
1025	EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimerâ€•™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 1-6.	1.5	21
1026	Corpus Callosum Tissue Loss and Development of Motor and Global Cognitive Impairment: The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 279-286.	1.5	24

#	ARTICLE	IF	CITATIONS
1027	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 353-366.	2.3	140
1028	An Informant Questionnaire for Detecting Alzheimer's Disease: Are Some Items Better Than Others?. Journal of the International Neuropsychological Society, 2011, 17, 674-681.	1.8	2
1029	Hippocampal Atrophy in Subcortical Vascular Dementia. Neurodegenerative Diseases, 2011, 8, 465-469.	1.4	51
1030	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 67-71.	1.9	42
1031	Disorders Mainly Affecting White Matter. , 2011, , 177-242.		1
1032	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
1033	White Matter Hyperintensities, Medial Temporal Lobe Atrophy, Cortical Atrophy, and Response to Electroconvulsive Therapy in Severely Depressed Elderly Patients. Journal of Clinical Psychiatry, 2011, 72, 104-112.	2.2	37
1034	How to Use This Book?. , 2011, , 1-3.		0
1035	Dementias with Associated "Brain Swelling"™. , 2011, , 243-268.		0
1036	Primary Grey Matter Loss. , 2011, , 59-135.		0
1037	The Toolbox. , 2011, , 13-42.		0
1038	Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 1083-1090.	2.6	30
1039	Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial. Trials, 2010, 11, 19.	1.6	45
1040	Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. European Journal of Neurology, 2010, 17, 90-96.	3.3	65
1041	EFNS guidelines for the diagnosis and management of Alzheimer's™ disease. European Journal of Neurology, 2010, 17, 1236-1248.	3.3	407
1042	Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic. Journal of the American Geriatrics Society, 2010, 58, 1318-1321.	2.6	11
1043	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2010, 29, 491-497.	1.5	38
1044	Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings. Alzheimer Disease and Associated Disorders, 2010, 24, 303-307.	1.3	26

#	ARTICLE	IF	CITATIONS
1045	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. Alzheimer Disease and Associated Disorders, 2010, 24, 242-247.	1.3	19
1046	Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2010, 29, 301-308.	1.5	6
1047	How Useful Is the IQCODE for Discriminating between Alzheimer's Disease, Mild Cognitive Impairment and Subjective Memory Complaints?. Dementia and Geriatric Cognitive Disorders, 2010, 30, 411-416.	1.5	35
1048	Amyloid- β (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. Clinical Chemistry, 2010, 56, 248-253.	3.2	301
1049	New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. Dementia and Geriatric Cognitive Disorders, 2010, 30, 1-7.	1.5	48
1050	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. Stroke, 2010, 41, e402-8.	2.0	82
1051	Can Nutrients Prevent or Delay Onset of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2010, 20, 765-775.	2.6	90
1052	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 547-551.	1.9	103
1053	Vascular Care in Patients With Alzheimer Disease With Cerebrovascular Lesions Slows Progression of White Matter Lesions on MRI. Stroke, 2010, 41, 554-556.	2.0	71
1054	Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. Clinical Neuropsychologist, 2010, 24, 203-219.	2.3	104
1055	Incidence of Depression and Anxiety in the Spouses of Patients With Dementia: A Naturalistic Cohort Study of Recorded Morbidity With a 6-Year Follow-Up. American Journal of Geriatric Psychiatry, 2010, 18, 146-153.	1.2	131
1056	The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 67-77.	10.1	1,505
1057	Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. Journal of the Neurological Sciences, 2010, 299, 19-23.	0.6	49
1058	Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychological Medicine, 2010, 40, 603-610.	4.5	119
1059	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiology of Aging, 2010, 31, 758-764.	3.1	90
1060	Evaluation of plasma A β 40 and A β 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 539-540.	3.1	19
1061	Inflammatory markers in AD and MCI patients with different biomarker profiles—interpretation of serum and CSF levels. Neurobiology of Aging, 2010, 31, 1655.	3.1	0
1062	Loss of "Small-World" Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity. PLoS ONE, 2010, 5, e13788.	2.5	523

#	ARTICLE	IF	CITATIONS
1063	Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. <i>Alzheimer's and Dementia</i> , 2010, 6, 1.	0.8	235
1064	F3-01-01: The development of a new IADL informant-based questionnaire: The Amsterdam IADL questionnaire. , 2010, 6, S115-S116.		0
1065	Simplified parametric methods for [¹⁸ F]FDDNP studies. <i>NeuroImage</i> , 2010, 49, 433-441.	4.2	7
1066	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [¹¹ C]PIB and [¹⁸ F]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884.	1.9	56
1067	Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1401-1408.	2.6	359
1068	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.	2.6	75
1069	CSF \pm -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	2.6	87
1070	Can novel therapeutics halt the amyloid cascade?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 5.	6.2	19
1071	Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 432-437.	1.5	60
1072	MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study. , 2010, , 275-282.		2
1073	Structural neuroimaging. , 2009, , 58-69.		31
1074	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 601-607.	2.6	45
1075	Most rapid cognitive decline in APOE ϵ 4 negative Alzheimer's disease with early onset. <i>Psychological Medicine</i> , 2009, 39, 1907-1911.	4.5	101
1076	Relationship of Cerebrospinal Fluid Markers to ¹¹ C-PiB and ¹⁸ F-FDDNP Binding. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1464-1470.	5.0	162
1077	Detection of Alzheimer Pathology In Vivo Using Both ¹¹ C-PiB and ¹⁸ F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.	5.0	119
1078	Hippocampal volume loss and Alzheimer disease progression. <i>Nature Reviews Neurology</i> , 2009, 5, 361-362.	10.1	22
1079	Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 18-23.	1.5	56
1080	Regional White Matter Integrity Differentiates Between Vascular Dementia and Alzheimer Disease. <i>Stroke</i> , 2009, 40, 773-779.	2.0	90

#	ARTICLE	IF	CITATIONS
1081	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477.	2.3	348
1082	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.	7.3	121
1083	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. <i>Stroke</i> , 2009, 40, 492-498.	2.0	118
1084	The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009, 132, 1287-1298.	7.6	277
1085	Vascular Factors and Markers of Inflammation in Offspring With a Parental History of Late-Onset Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2009, 66, 1263.	12.3	73
1086	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 235-240.	1.6	157
1087	CSF levels of PSA and PSAâ€“ACT complexes in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 477-483.	1.6	9
1088	Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2009, 348, 57-66.	1.4	21
1089	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. <i>BMC Neuroscience</i> , 2009, 10, 101.	1.9	317
1090	Autosomal recessive paraparesis with amyotrophy of the hands and feet. <i>Acta Neurologica Scandinavica</i> , 2009, 87, 443-445.	2.1	7
1091	Modelâ€“free group analysis shows altered BOLD fMRI networks in dementia. <i>Human Brain Mapping</i> , 2009, 30, 256-266.	3.6	129
1092	White matter tract integrity in aging and Alzheimer's disease. <i>Human Brain Mapping</i> , 2009, 30, 1051-1059.	3.6	227
1093	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusionâ€“weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq1 13047843143gBT /O	3.4	134
1094	Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies. <i>Molecular Imaging and Biology</i> , 2009, 11, 322-333.	2.6	20
1095	Test-retest variability of quantitative [11C]PIB studies in Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1629-1638.	6.4	62
1096	Nutrition and dementia. <i>European Journal of Neurology</i> , 2009, 16, iii-iv.	3.3	1
1097	Moving forward with nutrition in Alzheimerâ€™s disease. <i>European Journal of Neurology</i> , 2009, 16, 19-22.	3.3	18
1098	Accelerating regional atrophy rates in the progression from normal aging to Alzheimerâ€™s disease. <i>European Radiology</i> , 2009, 19, 2826-2833.	4.5	88

#	ARTICLE	IF	CITATIONS
1099	Patients With Alzheimer Disease With Multiple Microbleeds. <i>Stroke</i> , 2009, 40, 3455-3460.	2.0	202
1100	Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. <i>Brain</i> , 2009, 132, 213-224.	7.6	895
1101	Dementia: THE BARE ESSENTIALS. <i>Practical Neurology</i> , 2009, 9, 241-251.	1.1	35
1102	Progression of Mild Cognitive Impairment to Dementia. <i>Stroke</i> , 2009, 40, 1269-1274.	2.0	128
1103	Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> , 2009, 30, 1885-1889.	3.1	135
1104	CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1895-1901.	3.1	121
1105	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. <i>Cerebrovascular Diseases</i> , 2009, 27, 336-344.	1.7	78
1106	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.	1.7	167
1107	Can we do better in developing new drugs for Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2009, 5, 489-491.	0.8	25
1108	Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1614-1619.	7.1	256
1109	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	7.4	1,009
1110	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , The, 2009, 8, 619-627.	10.2	542
1111	Neuroanatomical and Neuropsychological Features of Euthymic Patients with Bipolar Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 1012-1021.	1.2	37
1112	The effect of anxiety and depression on decline of memory function in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 1142-1147.	1.0	16
1113	Imaging in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 191-199.	3.7	34
1114	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. , 2009, , 103-127.		0
1115	Are Biomarkers Valid as Surrogates for Treatment Effects in Alzheimer's Disease?. <i>European Neurological Review</i> , 2009, 4, 13.	0.5	0
1116	Progressive dementia and mesiotemporal atrophy on brain MRI: Neurosyphilis mimicking pre-senile Alzheimer's disease?. <i>European Journal of Neurology</i> , 2008, 15, e14-5.	3.3	17

#	ARTICLE	IF	CITATIONS
1117	The renin-angiotensin-aldosterone system in cerebral small vessel disease. Journal of Neurology, 2008, 255, 993-1000.	3.6	31
1118	Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. Journal of Neurology, 2008, 255, 1302-8.	3.6	86
1119	Small vessel versus large vessel vascular dementia. Journal of Neurology, 2008, 255, 1644-1651.	3.6	55
1120	(Cost)-effectiveness of family meetings on indicated prevention of anxiety and depressive symptoms and disorders of primary family caregivers of patients with dementia: design of a randomized controlled trial. BMC Geriatrics, 2008, 8, 2.	2.7	29
1121	Development of quality indicators for memory clinics. International Journal of Geriatric Psychiatry, 2008, 23, 119-128.	2.7	37
1122	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2008, 23, 387-392.	2.7	34
1123	Urinary Complaints in Nondisabled Elderly People with Age-Related White Matter Changes: The Leukoaraiosis And Disability (LADIS) Study. Journal of the American Geriatrics Society, 2008, 56, 1638-1643.	2.6	81
1124	Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. European Journal of Pharmacology, 2008, 585, 88-96.	3.5	95
1125	Alzheimer's disease: a broad overview. Lancet Neurology, The, 2008, 7, 31.	10.2	0
1126	Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurology, The, 2008, 7, 668-670.	10.2	21
1127	Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. Congestive Heart Failure, 2008, 14, 61-65.	2.0	41
1128	Global dynamical analysis of the EEG in Alzheimer's disease: Frequency-specific changes of functional interactions. Clinical Neurophysiology, 2008, 119, 837-841.	1.5	91
1129	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. Clinical Neurophysiology, 2008, 119, 1732-1738.	1.5	46
1130	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. Clinical Neurophysiology, 2008, 119, 2727-2732.	1.5	26
1131	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion, 2008, 24, 2561-2574.	1.9	124
1132	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging, 2008, 29, 669-675.	3.1	103
1133	Distortions in resting-state activity rhythm in aging relate to white matter hyperintensities. Neurobiology of Aging, 2008, 29, 1265-1271.	3.1	24
1134	The role of white matter hyperintensities and medial temporal lobe atrophy in age-related executive dysfunctioning. Brain and Cognition, 2008, 68, 128-133.	1.8	43

#	ARTICLE	IF	CITATIONS
1135	Detecting Alzheimer pathology in vivo: Comparing regional binding of [11C]PIB and [18F]FDDNP. NeuroImage, 2008, 41, T118.	4.2	0
1136	Simplified parametric methods for [11C]PIB studies. NeuroImage, 2008, 42, 76-86.	4.2	85
1137	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39
1138	Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.	1.8	1
1139	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain, 2008, 131, 3286-3298.	7.6	246
1140	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1300-4.	2.3	16
1141	Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. Cerebrovascular Diseases, 2008, 25, 247-253.	1.7	79
1142	Early-Onset Dementia Is Associated with Higher Mortality. Dementia and Geriatric Cognitive Disorders, 2008, 26, 147-152.	1.5	82
1143	Diagnostic Accuracy of Consensus Diagnostic Criteria for Frontotemporal Dementia in a Memory Clinic Population. Dementia and Geriatric Cognitive Disorders, 2008, 25, 157-164.	1.5	35
1144	Distribution of APOE Genotypes in a Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2008, 25, 433-438.	1.5	35
1145	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease & Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	1.5	8
1146	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. Stroke, 2008, 39, 317-322.	2.0	80
1147	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. Stroke, 2008, 39, 1414-1420.	2.0	348
1148	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 522-527.	1.5	27
1149	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. American Journal of Neuroradiology, 2008, 29, 1296-1301.	2.4	72
1150	White Matter Hyperintensities and Working Memory: An Explorative Study. Aging, Neuropsychology, and Cognition, 2008, 15, 384-399.	1.3	17
1151	White Matter Changes Contribute to Corpus Callosum Atrophy in the Elderly: The LADIS Study. American Journal of Neuroradiology, 2008, 29, 1498-1504.	2.4	51
1152	Amnesic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology, 2008, 29, 944-949.	2.4	162

#	ARTICLE	IF	CITATIONS
1153	Cognitive Impairment No Dementia – Neuropsychological and Neuroimaging Characterization of an Amnesic Subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 238-247.	1.5	18
1154	Simon B.ÂN. Thompson, <i>Dementia and Memory: A Handbook for Students and Professionals</i> , Ashgate, Aldershot, Hampshire, 2006, 256 pp., hbk Â£50.00, ISBN 13: 978Â0Â7546Â4633Â4.. <i>Ageing and Society</i> , 2008, 28, 137-138.	1.7	1
1155	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. <i>Radiology</i> , 2008, 248, 590-598.	7.3	133
1156	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease. <i>Neuroepidemiology</i> , 2008, 30, 254-265.	2.3	86
1157	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	2.0	76
1158	Resting-State Oscillatory Brain Dynamics in Alzheimer Disease. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 187-193.	1.7	75
1159	Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1003-1009.	7.1	130
1160	Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1325-1330.	1.9	136
1161	Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease. <i>Archives of Neurology</i> , 2007, 64, 849.	4.5	60
1162	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.	2.0	107
1163	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. <i>Archives of Neurology</i> , 2007, 64, 108.	4.5	178
1164	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	4.5	67
1165	Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. <i>Age and Ageing</i> , 2007, 36, 164-170.	1.6	135
1166	Comparison of the Alzheimer’s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81.	1.5	45
1167	Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 42-46.	1.5	49
1168	Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 418-423.	1.5	91
1169	Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer’s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1039-1039.	1.9	1
1170	Brain Lesions on MRI in Elderly Patients with Type 2 Diabetes Mellitus. <i>European Neurology</i> , 2007, 57, 70-74.	1.4	115

#	ARTICLE	IF	CITATIONS
1171	Cognitive Impairment in Alzheimer's Disease Is Modified by APOE Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 98-103.	1.5	66
1172	Nonlinear Changes in Brain Activity During Continuous Word Repetition: An Event-Related Multiparametric Functional MR Imaging Study. <i>American Journal of Neuroradiology</i> , 2007, 28, 1715-1721.	2.4	8
1173	Chapter 15 Advances in Neuroimaging. <i>Blue Books of Neurology</i> , 2007, 30, 381-410.	0.1	0
1174	All patients with suspected dementia should be scanned at least once with CT or MRI. <i>International Psychogeriatrics</i> , 2007, 19, 533-534.	1.0	2
1175	Clinical significance of corpus callosum atrophy in a mixed elderly population. <i>Neurobiology of Aging</i> , 2007, 28, 955-963.	3.1	67
1176	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007, 28, 1070-1074.	3.1	160
1177	Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. <i>Neurobiology of Learning and Memory</i> , 2007, 87, 57-66.	1.9	146
1178	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. <i>NeuroImage</i> , 2007, 34, 1036-1041.	4.2	39
1179	Hippocampal shape analysis in Alzheimer's disease: A population-based study. <i>NeuroImage</i> , 2007, 36, 8-18.	4.2	101
1180	SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods. <i>NeuroImage</i> , 2007, 35, 1473-1479.	4.2	26
1181	Cognitive impairment in heart failure: A systematic review of the literature. <i>European Journal of Heart Failure</i> , 2007, 9, 440-449.	7.1	445
1182	CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer's Disease and Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 225-230.	1.5	64
1183	Whole brain analysis of T2* weighted baseline fMRI signal in dementia. <i>Human Brain Mapping</i> , 2007, 28, 1313-1317.	3.6	32
1184	Evaluation of Methods for Generating Parametric (R)-[11C]PK11195 Binding Images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1603-1615.	4.3	32
1185	Evaluation of Reference Regions for (R)-[11C]PK11195 Studies in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1965-1974.	4.3	53
1186	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	2.3	88
1187	No evidence for increased self-reported cognitive failure in Type 1 and Type 2 diabetes: a cross-sectional study. <i>Diabetic Medicine</i> , 2007, 24, 735-740.	2.3	12
1188	ASSOCIATION BETWEEN VITAMIN B ₆ AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	2.6	10

#	ARTICLE	IF	CITATIONS
1189	Profile of Cognitive Impairment in Chronic Heart Failure. Journal of the American Geriatrics Society, 2007, 55, 1764-1770.	2.6	160
1190	Subcortical white matter pathology as a mediating factor for age-related decreased performance in dichotic listening. Neuropsychologia, 2007, 45, 2322-2332.	1.6	10
1191	Getting a grip on Alzheimer's disease: imaging amyloid in the brain. Lancet Neurology, The, 2007, 6, 204-206.	10.2	2
1192	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. Lancet Neurology, The, 2007, 6, 501-512.	10.2	314
1193	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
1194	Use of proteomic approaches to identify disease biomarkers. Lancet Neurology, The, 2007, 6, 1036-1037.	10.2	6
1195	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. Annals of the New York Academy of Sciences, 2007, 1097, 215-224.	3.8	27
1196	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology, 2007, 49, 967-976.	2.2	251
1197	Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. Diabetologia, 2007, 50, 1763-1769.	6.3	105
1198	Glucocorticoids Decrease Hippocampal and Prefrontal Activation during Declarative Memory Retrieval in Young Men. Brain Imaging and Behavior, 2007, 1, 31-41.	2.1	119
1199	Consistent resting-state networks across healthy subjects. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13848-13853.	7.1	3,817
1200	Mild cognitive impairment. Lancet, The, 2006, 367, 1262-1270.	13.7	2,401
1201	Attention modulates hemispheric differences in functional connectivity: Evidence from MEG recordings. NeuroImage, 2006, 30, 245-253.	4.2	33
1202	Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. NeuroImage, 2006, 32, 1335-1344.	4.2	282
1203	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 714-718.	1.9	539
1204	Progressive, isolated language disturbance: Its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. Journal of the Neurological Sciences, 2006, 240, 45-51.	0.6	14
1205	Pain intensity and pain affect in relation to white matter changes. Pain, 2006, 125, 74-81.	4.2	26
1206	Multicenter assessment of reliability of cranial MRI. Neurobiology of Aging, 2006, 27, 1051-1059.	3.1	96

#	ARTICLE	IF	CITATIONS
1207	White Matter Lesions Are Associated With Progression of Medial Temporal Lobe Atrophy in Alzheimer Disease. <i>Stroke</i> , 2006, 37, 2248-2252.	2.0	50
1208	Peripheral electrical nerve stimulation and rest-activity rhythm in Alzheimer's disease. <i>Journal of Sleep Research</i> , 2006, 15, 415-423.	3.2	14
1209	Diabetes and cognitive impairment. <i>Journal of Neurology</i> , 2006, 253, 477-482.	3.6	72
1210	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.	3.6	109
1211	Diabetic encephalopathy: a concept in need of a definition. <i>Diabetologia</i> , 2006, 49, 1447-1448.	6.3	176
1212	Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. <i>Diabetologia</i> , 2006, 49, 2474-2480.	6.3	156
1213	Risk of dementia in diabetes mellitus: a systematic review. <i>Lancet Neurology</i> , The, 2006, 5, 64-74.	10.2	1,791
1214	Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. <i>Neuropsychologia</i> , 2006, 44, 208-217.	1.6	66
1215	Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research. , 2006, 109, 274-283.		16
1216	Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 983-989.	2.7	94
1217	Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. <i>Neuroepidemiology</i> , 2006, 27, 101-116.	2.3	67
1218	Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. <i>Brain</i> , 2006, 129, 141-157.	7.6	110
1219	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	2.0	31
1220	Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males. <i>Neuropsychopharmacology</i> , 2006, 31, 1508-1518.	5.4	38
1221	Impact of diagnostic disclosure in dementia on patients and carers: Qualitative case series analysis. <i>Aging and Mental Health</i> , 2006, 10, 525-531.	2.8	73
1222	Impact of White Matter Hyperintensities Scoring Method on Correlations With Clinical Data. <i>Stroke</i> , 2006, 37, 836-840.	2.0	269
1223	Microvascular Disease in Type 1 Diabetes Alters Brain Activation: A Functional Magnetic Resonance Imaging Study. <i>Diabetes</i> , 2006, 55, 334-340.	0.6	63
1224	Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. <i>Multiple Sclerosis Journal</i> , 2006, 12, 760-768.	3.0	53

#	ARTICLE	IF	CITATIONS
1225	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 491-496.	1.9	90
1226	Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease. <i>Archives of Neurology</i> , 2006, 63, 538.	4.5	268
1227	The Auditory Oddball Paradigm in Patients with Vascular Cognitive Impairment: A Prolonged Latency of the N ₂ Complex. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 322-327.	1.5	11
1228	Receiving a diagnosis of dementia. <i>Dementia</i> , 2006, 5, 397-410.	2.0	78
1229	Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes. <i>Cerebrovascular Diseases</i> , 2006, 21, 315-322.	1.7	164
1230	Effects of High-Frequency Cranial Electrostimulation on the Rest-Activity Rhythm and Salivary Cortisol in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 267-272.	1.5	14
1231	Brain Imaging in Patients With Diabetes. <i>Diabetes Care</i> , 2006, 29, 2539-2548.	8.6	317
1232	Usefulness of Longitudinal Measurements of β -Amyloid β 42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. <i>Clinical Chemistry</i> , 2006, 52, 1604-1606.	3.2	16
1233	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 530-531.	2.5	3
1234	Brain Aging in Very Old Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2268-2274.	8.6	172
1235	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	4.5	14
1236	Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. <i>Journal of Nutrition, Health and Aging</i> , 2006, 10, 123-8; discussion 129-30.	3.3	8
1237	A 24-year follow-up of body mass index and cerebral atrophy. <i>Neurology</i> , 2005, 64, 1990-1991.	1.1	0
1238	Retrograde amnesia for semantic information in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 40-48.	1.8	5
1239	The impact of diagnostic disclosure in dementia: a qualitative case analysis. <i>International Psychogeriatrics</i> , 2005, 17, 319-326.	1.0	21
1240	LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1073-1074.	2.6	22
1241	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. <i>Human Brain Mapping</i> , 2005, 26, 231-239.	3.6	675
1242	Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?. <i>Annals of Neurology</i> , 2005, 58, 139-142.	5.3	112

#	ARTICLE	IF	CITATIONS
1243	Cerebrospinal fluid tau levels in frontotemporal dementia. <i>Annals of Neurology</i> , 2005, 58, 656-657.	5.3	9
1244	Effects of Processing and Storage Conditions on Amyloid β (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 189-195.	3.2	151
1245	Functional Connectivity in Elderly Controls and AD Patients Using Resting State fMRI: A Pilot Study. <i>Current Alzheimer Research</i> , 2005, 2, 115-116.	1.4	38
1246	Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 524-531.	3.0	121
1247	Differences and Similarities between Two Frequently Used Assays for Amyloid β 42 in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2005, 51, 1057-1060.	3.2	9
1248	Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 126-133.	1.5	28
1249	Peripheral Electrical Stimulation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 361-368.	1.5	6
1250	Blood Pressure, White Matter Lesions and Medial Temporal Lobe Atrophy: Closing the Gap between Vascular Pathology and Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 331-337.	1.5	23
1251	Differential Regional Atrophy of the Cingulate Gyrus in Alzheimer Disease: A Volumetric MRI Study. <i>Cerebral Cortex</i> , 2005, 16, 1701-1708.	2.9	131
1252	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	2.0	311
1253	Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2005, 116, 708-715.	1.5	224
1254	Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. <i>NeuroImage</i> , 2005, 24, 898-909.	4.2	182
1255	Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. <i>NeuroImage</i> , 2005, 25, 63-75.	4.2	37
1256	Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. <i>NeuroImage</i> , 2005, 26, 1078-1085.	4.2	129
1257	Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 69-84.	2.6	105
1258	Biomarker profiles and their relation to clinical variables in mild cognitive impairment. <i>Neurocase</i> , 2005, 11, 8-13.	0.6	47
1259	The transmethylation cycle in the brain of Alzheimer patients. <i>Neuroscience Letters</i> , 2005, 386, 69-71.	2.1	48
1260	Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability - The LADIS Study: Rationale, Design and Methodology. <i>Neuroepidemiology</i> , 2005, 24, 51-62.	2.3	387

#	ARTICLE	IF	CITATIONS
1261	Effects of reference tissue versus plasma input parametric kinetic modelling on statistical parametric analysis of [¹¹ C](R)-PK11195 binding in Alzheimer's disease (AD) and young and old subjects. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S643-S643.	4.3	2
1262	Midlife Blood Pressure and the Risk of Hippocampal Atrophy. Hypertension, 2004, 44, 29-34.	2.7	228
1263	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology, 2004, 63, 94-100.	1.1	307
1264	Validation of the HIV Dementia Scale in an Elderly Cohort of Patients with Subcortical Cognitive Impairment Caused by Subcortical Ischaemic Vascular Disease or a Normal Pressure Hydrocephalus. Dementia and Geriatric Cognitive Disorders, 2004, 18, 109-114.	1.5	16
1265	An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 549-555.	3.0	65
1266	Regional Distribution of White Matter Hyperintensities in Vascular Dementia, Alzheimer's Disease and Healthy Aging. Dementia and Geriatric Cognitive Disorders, 2004, 18, 180-188.	1.5	144
1267	Thalamic Lesions in Vascular Dementia. Stroke, 2004, 35, 415-419.	2.0	52
1268	White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology, 2004, 62, 310-312.	1.1	119
1269	Advances in the early detection of Alzheimer's disease. Nature Medicine, 2004, 10, S34-S41.	30.7	401
1270	P3-043 Inflammatory markers CRP and IL-6 in cerebrospinal fluid and serum in relation to the IL-6 genotype in patients with Alzheimer's disease. Neurobiology of Aging, 2004, 25, S363-S364.	3.1	0
1271	P4-316 The methionine-homocysteine cycle in the brain of Alzheimer patients. Neurobiology of Aging, 2004, 25, S565.	3.1	0
1272	P3-063 Activation in the working memory network in healthy aging, mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2004, 25, S369-S370.	3.1	0
1273	MRI and CT in the diagnosis of vascular dementia. Journal of the Neurological Sciences, 2004, 226, 9-12.	0.6	65
1274	P3-096 Effects of galantamine challenge on episodic and working memory systems in patients with mild cognitive impairment: an FMRI study. Neurobiology of Aging, 2004, 25, S381-S382.	3.1	0
1275	Initial Complaints in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2004, 17, 302-306.	1.5	52
1276	Biomarkers for Alzheimer's disease. Which way to go?. Neurobiology of Aging, 2004, 25, 695-696.	3.1	5
1277	EEG synchronization likelihood in mild cognitive impairment and Alzheimer's disease during a working memory task. Clinical Neurophysiology, 2004, 115, 1332-1339.	1.5	227
1278	Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. NeuroImage, 2004, 21, 173-180.	4.2	32

#	ARTICLE	IF	CITATIONS
1279	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage</i> , 2004, 23, 708-716.	4.2	522
1280	Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. <i>NeuroImage</i> , 2004, 23, 1450-1459.	4.2	104
1281	P2-200 Patterns of brain atrophy in early-onset versus late-onset Alzheimer's disease: relevance of posterior cingulate atrophy. <i>Neurobiology of Aging</i> , 2004, 25, S285-S286.	3.1	0
1282	P2-201 Microglia activation in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2004, 25, S286.	3.1	3
1283	P2-227 A comparison of medial temporal lobe atrophy ratings with linear and volumetric measures in aging and dementia. <i>Neurobiology of Aging</i> , 2004, 25, S296.	3.1	0
1284	Pathological Aging of the Brain. <i>Topics in Magnetic Resonance Imaging</i> , 2004, 15, 369-389.	1.2	60
1285	Neuroimaging in old age psychiatry. <i>Current Opinion in Psychiatry</i> , 2004, 17, 449-452.	6.3	2
1286	Memantine in Moderate-to-Severe Alzheimer Disease Evidence and Ethics Based?. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 47-48.	1.3	6
1287	Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2003, 110, 949-955.	2.8	163
1288	Treatment of Alzheimer's disease; current status and new perspectives. <i>Lancet Neurology</i> , The, 2003, 2, 539-547.	10.2	664
1289	Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. <i>Neuropsychologia</i> , 2003, 41, 1330-1344.	1.6	363
1290	Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. <i>Annals of Neurology</i> , 2003, 53, 547-548.	5.3	115
1291	EEG synchronization in mild cognitive impairment and Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 90-96.	2.1	248
1292	A paced visual serial addition test for fMRI. <i>Journal of the Neurological Sciences</i> , 2003, 213, 29-34.	0.6	82
1293	A neural complexity measure applied to MEG data in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2003, 114, 1034-1040.	1.5	59
1294	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. <i>NeuroImage</i> , 2003, 18, 895-907.	4.2	388
1295	Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging. <i>Stroke</i> , 2003, 34, 441-445.	2.0	271
1296	Identifying confounds to increase specificity during a fMRI task condition. <i>NeuroImage</i> , 2003, 20, 1236-1245.	4.2	81

#	ARTICLE	IF	CITATIONS
1297	Tau and A β 242 protein in CSF of patients with frontotemporal degeneration. <i>Neurology</i> , 2003, 60, 353-354.	1.1	4
1298	Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. <i>Brain</i> , 2003, 126, 2016-2022.	7.6	423
1299	Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia. <i>Stroke</i> , 2003, 34, 1907-1912.	2.0	158
1300	White-Matter Changes on MRI as Surrogate Marker. <i>International Psychogeriatrics</i> , 2003, 15, 261-265.	1.0	10
1301	Total tau and Phosphorylated tau 181 Levels in the Cerebrospinal Fluid of Patients With Frontotemporal Dementia Due to P301L and G272V tau Mutations. <i>Archives of Neurology</i> , 2003, 60, 1209-13.	4.5	69
1302	Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Non-Pain Related Cognitive and Behavioural Functioning. <i>Reviews in the Neurosciences</i> , 2002, 13, 257-70.	2.9	17
1303	Imaging of White Matter Lesions. <i>Cerebrovascular Diseases</i> , 2002, 13, 21-30.	1.7	128
1304	Generalized Synchronization of MEG Recordings in Alzheimer's Disease: Evidence for Involvement of the Gamma Band. <i>Journal of Clinical Neurophysiology</i> , 2002, 19, 562-574.	1.7	242
1305	A new rapid landmark-based regional MRI segmentation method of the brain. <i>Journal of the Neurological Sciences</i> , 2002, 194, 35-40.	0.6	36
1306	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. <i>Lancet Neurology</i> , The, 2002, 1, 13-21.	10.2	337
1307	Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. <i>Journal of Neural Transmission</i> , 2002, 109, 1203-1208.	2.8	30
1308	CSF markers related to pathogenetic mechanisms in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 1491-1498.	2.8	32
1309	Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. <i>Journal of Neurology</i> , 2002, 249, 312-319.	3.6	51
1310	Magnetic Resonance and Dementia. , 2002, , 1-4.		1
1311	Head trauma and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 303-308.	2.6	36
1312	Magnetic Resonance: Applications in Dementia. , 2002, , 5-25.		0
1313	Neurodegenerative Disorders. , 2002, , 31-138.		0
1314	The role of the parahippocampal cortex in spatial memory: an fMRI Study. <i>NeuroImage</i> , 2001, 13, 703.	4.2	0

#	ARTICLE	IF	CITATIONS
1315	Anterior Medial Temporal Lobe Activation during Attempted Retrieval of Encoded Visuospatial Scenes: An Event-Related fMRI Study. <i>NeuroImage</i> , 2001, 14, 67-76.	4.2	63
1316	Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2001, 358, 455-460.	13.7	212
1317	Structural neuroimaging of Alzheimer's disease and other dementias. <i>Aging Clinical and Experimental Research</i> , 2001, 13, 203-209.	2.9	15
1318	Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: Atypical molecular phenotype. <i>Annals of Neurology</i> , 2001, 50, 258-261.	5.3	27
1319	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.	2.0	1,506
1320	Functional MRI of cortex in sedated 18 month-old infants with or without periventricular leukomalacia. <i>Developmental Medicine and Child Neurology</i> , 2001, 43, 486.	2.1	33
1321	Genetic and biochemical markers for Alzheimer's disease: recent developments. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 593-607.	1.6	32
1322	Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. <i>Current Opinion in Neurology</i> , 2000, 13, 391-396.	3.6	61
1323	fMRI of visual encoding: Reproducibility of activation. , 2000, 9, 156-164.		201
1324	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. <i>Hippocampus</i> , 2000, 10, 398-410.	1.9	323
1325	MRI volumetric correlates of white matter lesions in dementia with lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 911-916.	2.7	80
1326	Limitations of Clinical Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution?. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 262-272.	3.8	100
1327	Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 442-445.	3.8	69
1328	Preliminary Results from an MRI/CT-Based Database for Vascular Dementia and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 542-546.	3.8	30
1329	L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2000, 107, 183-189.	2.8	51
1330	Aspects of Alzheimer's disease. <i>Lancet, The</i> , 2000, 355, 1920.	13.7	2
1331	Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. <i>Neuroscience Letters</i> , 2000, 285, 231-233.	2.1	145
1332	Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. <i>Clinical Neurophysiology</i> , 2000, 111, 604-612.	1.5	145

#	ARTICLE	IF	CITATIONS
1333	Corticoâ€‘hippocampal communication by way of parallel parahippocampalâ€‘subicular pathways. Hippocampus, 2000, 10, 398-410.	1.9	11
1334	Diagnosis and management of Alzheimerâ€™s disease and other disorders associated with dementia. The role of neurologists in Europe. European Journal of Neurology, 2000, 7, 133.	3.3	63
1335	Early diagnosis of dementia: neuroimaging. Journal of Neurology, 1999, 246, 16-20.	3.6	100
1336	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of Neurology, 1999, 246, 477-485.	3.6	298
1337	Parametric fMRI analysis of visual encoding in the human medial temporal lobe. , 1999, 9, 637-643.		41
1338	Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Research - Neuroimaging, 1999, 90, 193-199.	1.8	58
1339	The diagnostic value of electroencephalography in mild senile Alzheimer's disease. Clinical Neurophysiology, 1999, 110, 825-832.	1.5	97
1340	Apolipoprotein E �4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. Archives of Neurology, 1999, 56, 961.	4.5	82
1341	Vascular Dementia: The Role of Cerebral Infarcts. Alzheimer Disease and Associated Disorders, 1999, 13, S38-S48.	1.3	30
1342	Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychological Medicine, 1999, 29, 181-187.	4.5	51
1343	Role of White Matter Lesions in Cognitive Impairment of Vascular Origin. Alzheimer Disease and Associated Disorders, 1999, 13, S49-54.	1.3	47
1344	Imaging of Static Brain Lesions in Vascular Dementia. Alzheimer Disease and Associated Disorders, 1999, 13, S81-90.	1.3	29
1345	Within-Subject Reproducibility of Visual Activation Patterns With Functional Magnetic Resonance Imaging Using Multislice Echo Planar Imaging. Magnetic Resonance Imaging, 1998, 16, 105-113.	1.8	163
1346	White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. European Neurology, 1998, 39, 80-89.	1.4	244
1347	Pathophysiologic Mechanisms in the Development of Age-Related White Matter Changes of the Brain. Dementia and Geriatric Cognitive Disorders, 1998, 9, 2-5.	1.5	156
1348	Cooperation and Networking on White Matter Disorders: The European Task Force on Age-Related White Matter Changes. Dementia and Geriatric Cognitive Disorders, 1998, 9, 44-45.	1.5	10
1349	Emerging Treatments in Dementia. European Neurology, 1997, 38, 184-189.	1.4	3
1350	The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m-HMPAO Single-Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community-Dwelling Elderly Population. Alzheimer Disease and Associated Disorders, 1997, 11, 63-70.	1.3	55

#	ARTICLE	IF	CITATIONS
1351	Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging. <i>European Neurology</i> , 1997, 37, 95-99.	1.4	166
1352	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1997, 15, 155-162.	1.8	43
1353	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997, 7, 594-601.	1.9	134
1354	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997, 7, 594-601.	1.9	2
1355	Familial spastic paraplegia: evidence for a fourth locus. <i>Clinical Neurology and Neurosurgery</i> , 1997, 99, 87-90.	1.4	3
1356	Diagnosing Alzheimer's Disease in Community-Dwelling Elderly: A Comparison of EEG and MRI. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 198-202.	1.5	20
1357	Circadian restâ€”activity rhythm disturbances in alzheimer's disease. <i>Biological Psychiatry</i> , 1996, 40, 259-270.	1.3	393
1358	The functional basis of ocular dominance: functional MRI (fMRI) findings. <i>Neuroscience Letters</i> , 1996, 221, 1-4.	2.1	105
1359	Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. <i>European Neurology</i> , 1996, 36, 268-272.	1.4	383
1360	Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. <i>Journal of Neurology</i> , 1995, 242, 557-560.	3.6	352
1361	No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. <i>Clinica Chimica Acta</i> , 1995, 240, 99-102.	1.1	4
1362	A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. <i>Clinical Neurology and Neurosurgery</i> , 1995, 97, 307-313.	1.4	33
1363	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. <i>Neuroradiology</i> , 1994, 36, 382-387.	2.2	53
1364	Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with â€œprobable Alzheimer's diseaseâ€•. <i>Biological Psychiatry</i> , 1994, 36, 708-709.	1.3	4
1365	Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis. <i>Journal of the Neurological Sciences</i> , 1994, 125, 206-211.	0.6	30
1366	Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. <i>Journal of the Neurological Sciences</i> , 1994, 121, 46-49.	0.6	113
1367	Clinical neurophysiology in the diagnosis of Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 1994, 96, 111-118.	1.4	11
1368	Evidence for Atrophy of the Corpus callosum in Alzheimerâ€™s Disease. <i>European Neurology</i> , 1994, 34, 83-86.	1.4	30

#	ARTICLE	IF	CITATIONS
1369	Small Infarcts in the Centrum ovale: Study of Predisposing Factors. Cerebrovascular Diseases, 1994, 4, 83-87.	1.7	23
1370	Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device. Journal of Neuro-Oncology, 1993, 15, 269-273.	2.9	18
1371	SPECT, CT and MRI in a Turkish family with huntington's disease. Neuroradiology, 1993, 35, 525-528.	2.2	5
1372	A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. Journal of the Neurological Sciences, 1993, 114, 7-12.	0.6	870
1373	Neuro-imaging in the diagnosis of Alzheimer's disease. Clinical Neurology and Neurosurgery, 1993, 95, 81-91.	1.4	20
1374	Pre- and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. Journal of the Neurological Sciences, 1993, 117, 175-178.	0.6	15
1375	(99mTc)-HM-PAO SPECT and dementia in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 981-981.	1.9	4
1376	Frontal Lobe Dysfunction in Unilateral Lenticulostriate Infarcts. Archives of Neurology, 1992, 49, 1285.	4.5	63
1377	Leuko-Araiosis: Relationship with the Types of Focal Lesions Occurring in Acute Cerebrovascular Disorders. Cerebrovascular Diseases, 1992, 2, 169-176.	1.7	49
1378	Neuro-imaging in the diagnosis of Alzheimer's disease I. Computer tomography and magnetic resonance imaging. Clinical Neurology and Neurosurgery, 1992, 94, 277-289.	1.4	29
1379	Intracerebral haemorrhage in Sneddon's syndrome. Journal of the Neurological Sciences, 1992, 111, 227-228.	0.6	15
1380	White-matter lesions on CT in Alzheimer patients. Acta Neurologica Scandinavica, 1991, 84, 264-264.	2.1	5
1381	Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium-enhanced STIR imaging. Neuroradiology, 1991, 33, 70-71.	2.2	19
1382	A Dutch family with autosomal dominant pure spastic paraparesis (Strömper's disease). Acta Neurologica Scandinavica, 1990, 82, 169-173.	2.1	25
1383	Intracranial ganglioglioma: MR imaging.. American Journal of Roentgenology, 1990, 155, 899-900.	2.2	1
1384	Anterolateral lumbar meningocele presenting as an ovarian cyst, in a patient with neurofibromatosis. Clinical Neurology and Neurosurgery, 1989, 91, 351-354.	1.4	5
1385	Man with subjective complaints but abnormal CSF. , 0, , 13-17.		0
1386	Cerebrospinal fluid biomarkers of frontotemporal lobar degeneration. , 0, , 143-152.		0